Tender Ref. No: UPMSCL/QC-006/011/25-26 **Dated : 01.08.2025**

UTTAR PRADESH MEDICAL SUPPLIES CORPORATION LIMITED

(A Government of Uttar Pradesh Undertaking)

Regd. Office: SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension, Lucknow-226002

Website: https://etender.up.nic.in, www.upmsc.in

Email: quality@upmsc.in, Tel. no. 0522-2838102

E - TENDER FOR

THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE ANALYSIS OF DRUGS & DIAGNOSTIC KITS

LAST DATE FOR ONLINE SUBMISSION OF TENDER : 22.08.2025

e - TENDER FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE ANALYSIS OF DRUGS & DIAGNOSTIC KITS

e- TENDER SCHEDULE

TENDER REFERENCE	:	**Ref.: UPMSCL/QC-006/011/25-26,Dated: 01.08.2025**
TENDER WEBSITE	:	**http:etender.up.nic.in**
DATE AND TIME OF UPLOADING TENDER	:	01 - August - 2025, at 17:30 Hrs.
DATE AND TIME OF DOWNLOADING THE TENDER	:	01 - August - 2025, at 18:00 Hrs.
LAST DATE AND TIME FOR ONLINE SUBMISSION OF TENDER	:	22 – August- 2025, UPTO 15:00 Hrs
PRE-BID MEETING	:	08 - August, 2025, 12:30 Hrs at SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension, Lucknow-226002 (Before Pre-BID meeting, all Bidder's should send BID related query online through e-mail ID quality@upmsc.in till 07.08.2025 (17:00 Hrs)
DATE AND TIME OF OPENING OF **TECHNICAL BID-COVER 'A'**	:	22 – August- 2025 at 15:30 Hrs at UPMSCL Office, Lucknow.
DATE AND TIME OF OPENING OF **FINANCIAL BID- COVER 'B'**(PRICE/ BOQ)	:	Date shall be declared on website www.etender.up.nic.in and www.upmsc.in
DATE OF COMPLETION OF EXAMINATION OF FINANCIAL BID (PRICE/BOQ)	:	Date shall be declared on website www.etender.up.nic.in and www.upmsc.in
VALIDITY OF TENDER	:	180 DAYS
OPENING OF TENDER	:	**Online on http://etender.up.nic.in**
ADDRESS FOR COMMUNICATION	:	**Uttar Pradesh Medical Supplies Corporation Ltd**., SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension, Lucknow -226002 (UP) India
TENDER PROCESSING FEES	:	Rs. **5,900/-**(Rupees Five thousand nine hundred only) Plus GST as applicable (Non - Refundable), through RTGS /NEFT

MANAGING DIRECTOR
UPMSCL

Contents

SECTION I

DESCRIPTION, DIRECTIVE & ABBREVIATIONS

SECTION- I

DESCRIPTION, DIRECTIVE & ABBREVIATIONS

(1) **The Uttar Pradesh Medical Supplies Corporation Ltd** (UPMSCL) is a Government of Uttar Pradesh undertaking incorporated under Companies Act, 2013 on 23rd March, 2018 which has been set up for providing timely and effective Health Care Services to the people of Uttar Pradesh. The key objective of the UPMSCL is to act as the central procurement agency for all essential and specialized drugs, medical devices etc. of good quality and also equipments for the health care institutions having highest standards at competitive rates for various departments of the State providing health care to the people of U.P.

(2) The Managing Director, **Uttar Pradesh Medical Supplies Corporation Ltd**, SUDA Bhawan, 7/23, Sector-7, Gomti Nagar, Extension, Lucknow-226002, (hereinafter referred as **Tender Inviting Authority**) invites **e-Tender for the Empanelment of Analytical Testing Laboratories for the Analysis of Drugs & Diagnostic Kits,** for a period of **Two Year** from the date of agreement of the Tender. The duration of the rate contract agreement shall initially be for a period of Two (02) years from the date of execution of the agreement or as specified in the contract commencement notice. However the validity of agreement may be extended further on mutual consent of both the parties for a period of up to six (06) months at a time, subject to a maximum cumulative extension of (01) year beyond the original agreement period..Such extension(s), if any, shall be made on the same terms, conditions, and approved rates as agreed upon in the original contract.

(3) Tender documents may be viewed or downloaded online by interested and eligible Bidders from the website **www.upmsc.in or http://etender.up.nic.in** on mentioned dates after online payment of Tender Fees of Rs. **5,900/- (Rupees Five thousand nine hundred)** + **GST** as applicable (Non - Refundable), through RTGS /NEFT into the account of UPMSCL.

(4) Bidders can submit their tender online at **www.upmscl.in** or **http://etender.up.nic.in** on or before the “Last date and time” mentioned.

(5) Language of BID: English

(6) Bidder; Analytical Laboratory participating in Tender process for Analysis.

(7) All tenderes must be accompanied with Earnest Money Deposit. Scanned copy of the Earnest Money Deposit instrument should be uploaded online with the tender. **The Earnest Money Deposit** shall be **Rs.2,00,000/- (Rupees Two Lakh)** which should be deposited online through RTGS/NEFT into the account of UPMSCL, Lucknow. The Earnest Money deposit in any other form will not be accepted.

(8) It is essential to submit the original documents of tender fees, EMD, in sealed envelope at the office of UPMSCL, SUDA Bhawan, 7/23, Sector-7, Gomti Nagar, Extension, Lucknow-226002, as per e-Tender Schedule.

(9) Tender System : 2 cover system, **Cover – A : Technical Bid**, EMD & Prequalification,
Cover – B: Price Bid / Bill of Quantity (BOQ)

(10) Schedule of events : As per online tender time schedule (Key dates) on
https://etender.up.nic.in and www.upmsc.in

(11) Validity of BID : 180 Days from last date of bid submission. Prior to expiration of the BID validity, the Tender inviting authority may request the Bidder to extend the bid validity for further period as deemed fit.

(12) Validity of contract : Two Year as per agreement.

(13) The venue for Pre-bid meeting, opening of Technical Bid and Financial Bid shall be Office of Uttar Pradesh Medical Supplies Corporation Limited, SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension, Lucknow-226002.

(14) All further notifications/amendments, if any shall be posted on **www.upmsc.in or http://etender.up.nic.in** only. No separate communication shall be made with the individual Bidders. The bidders shall be solely responsible for checking the websites for any addendum/amendment issued subsequently to the bid document and take into consideration the same while preparing and submitting the bids. Bids will be opened online.

(15) Address for communication: **Uttar Pradesh Medical Supplies Corporation Limited**
SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension,
Lucknow-226002
E-mail:- quality@upmsc.in

.

.

ABBREVIATIONS

UPMSCL	Uttar Pradesh Medical Supplies Corporation Ltd.
EMD	Earnest Money Deposit
TIA	Tender Inviting Authority
MD	Managing Director
WHO	World Health Organization
GMP	Good Manufacturing Practices
QA	Quality Assurance
COA	Certificate of Analysis
SQ	Standard Quality
NSQ	Not of Standard Quality
PO	Purchase Order
LD	Liquidated Damage
GLP	Good Laboratory Practices
IP	Indian Pharmacopeia
BP	British Pharmacopeia
USP	United States Pharmacopeia
IHS	In-House Specification
NABL	National Accreditation Board for Testing and Calibration Laboratories
GST	Goods & Services Tax
RTGS	Real Time Gross Settlement
NEFT	National Electronic Fund Transfer
DSC	Digital Signature Certificate
EDL	Essential Drug List
Non - EDL	Non - Essential Drug List
UDIN	Unique Document Identification Number
DSC	Digital Signature Certificate

SECTION II

IMPORTANT INFORMATION FOR BIDDERS

IMPORTANT INFORMATION FOR BIDDERS

1. ELIGIBILITY CRITERIA

1.1. Analytical laboratory should have valid license for the analysis of drugs & diagnostic kits under the Drugs and Cosmetics Act, 1940 and Rules there under (including amendments in force currently) from the concerned State Drug Licensing Authority and should comply with provisions prescribed under Schedule L-1 of Drugs and Cosmetics Rules, 1945. The Bidder shall provide a valid certificate from regulatory authority in this respect.

1.2. Analytical Laboratory should be accredited by "National Accreditation Board for Testing and Calibration Laboratories" (NABL) and such accreditation should be valid on the date of submission of tender. Government Laboratories are exempted from NABL accreditation. The Bidder should submit valid certified copy of Accreditation along with category wise approved scope issued by NABL The laboratory should have NABL accreditation (Category wise approved Scope as per **Format- XIV**) for pharmaceuticals Formulation prescribed in the IP, BP,USP or other recognized Pharmacopoeia currently in force with respect to the drugs & diagnostic kits mentioned in **Annexure-XI, XII & XIII**. For Non-Pharmacopoeial products the Laboratory using Non- Pharmacopoeial protocols should have NABL accreditation for tests being carried out by the Laboratory.

1.3. Analytical Laboratories should have three years experience in the analysis of drugs & diagnostic kits as mentioned **Annexure- XI, XII & XIII.** Analytical Laboratory should provide a certificate issued by Licensing Authority. All documents related to experience should be annexed as **Annexure no-X**)

1.4. Analytical laboratory should have average annual turnover of Rs 1,00,00,000 (Rupees One Crore) for last three Financial years i.e. 2021-2022, 2022-2023 and 2023-2024. (As per Format- V)

1.5. Notarized photocopy of GLP (Good laboratory practice) Certificate issued by the state drug licensing authority **(Annexure No.VI).**

1.6. Notarized copy of non-Conviction certificate issued by drug licensing authority /competent authority of concern state is either currently valid or Issued within 6 months prior to bid submission end date for all premises **(Annexure- VII)**

1.7. A declaration that the Bidder has not been blacklisted debarred by any central/State Government organization and that the Bidder has not been convicted by any court of law violation under drug and cosmetic act and rules there under (As per **Format -VI**).

1.8. Agents of Analytical Laboratories are not eligible to participate in the tender.

1.9. Analytical Laboratory which is engaged in the manufacturing activity, shall not be eligible to participate in the tender.

Note : Government Laboratories are exempted from turnover clause, Tender fee, EMD and Performance security.

2. EARNEST MONEY DEPOSIT (EMD)

2.1. The Earnest Money Deposit shall be **Rs.2,00,000=00 (Rupees two lakh)** which should be deposited online through RTGS/NEFT into the account of UPMSCL. The Earnest Money deposit in any other form will not be accepted.

2.2. EMD acts as a safeguard against bidder's withdrawing/altering its bid during the bid validity period which is 180 days. Submission of EMD shall be mandatory unless exempted. EMD shall be submitted online through RTGS/NEFT to the account details mentioned below and receipt of the same shall be uploaded in e-Tender portal along with other documents. EMD shall be deposited from bank account of bidder only. Following are the Bank details for transaction.

Account Holder Name	U.P Medical Supplies Corporation Limited
Bank Name	State Bank of India
Branch	Arjunganj, Lucknow
Account No.	39366886265
IFSC code	SBIN0012732

(E-Transfer receipt has to be uploaded with the Tender & UTR No. Should be mentioned clearly)

2.3 Holding of EMD

The EMD shall be held for a period of 45 days beyond bid validity period of 180 days. Should it become necessary to extend the validity of the bids and the bid securities, UPMSCL shall request in writing/e-mail to all those who submitted bids for such extension before the expiry date thereof. Bidders shall have the right to refuse to grant such extension without forfeiting their bid securities. The bidders who refuse to grant the UPMSCL's request for an extension of the validity of their bids and bid securities, will have their bid securities returned to them. They shall be deemed to have waived their right to further participate in that bidding.

2.4 Forfeiture of EMD

EMD of a bidder shall be forfeited, if the bidder withdraws or amends his tender or impairs or derogates from the tender in any respect after expiry of the deadline for the receipt of tender but within the period of validity of tender. Further, if the successful bidder fails to furnish the required performance security within the specified period, his EMD will be liable to be forfeited. For partial default or non-acceptance of contract for any item (on justified ground like typographical error in quoted rate), 10 % shall be forfeited from the EMD. If the amount would be higher than the EMD amount itself then the bidder has to pay the difference amount within 10 days of such intimation & in case of non-compliance the bidder shall be debarred from doing business with UPMSCL for 2 years.

2.5 Refund of EMD

. EMD furnished by all unsuccessful bidders shall be returned to them without any interest whatsoever, not later than 30 (thirty) days after conclusion of the contract. EMD of the successful bidder shall be

returned, without any interest whatsoever, after receipt of performance security as called for in the contract

3. CLARIFICATION OF BIDDING DOCUMENTS

A prospective Bidder requiring any clarification of the Bidding Documents may notify the UPMSCL in writing or by e-mail at the Managing Director's mailing address indicated in the Invitation for Bids. Tender inviting authority reserves the right to take decision on nature and extent of amendments required.

4. AMENDMENT OF BIDDING DOCUMENTS

At any time prior to the deadline for online submission of bids, the **Tender Inviting Authority** (TIA) may, for any reason, whether at its own initiative or in response to a clarification requested by a prospective bidder, modify the Bidding Documents by an amendment. All such amendments will be made available on https://etender.up.nic.in and www.upmsc.in website. In order to allow prospective bidders reasonable time in which to take the amendment into account in preparing their bid, the TIA may, at its discretion, extend the deadline for the submission of bids.

5. THE TENDER PROCESS

The tender process will be of 2 cover system, consisting:

Cover - A: Technical Bid

Cover – B: Price Bid

5.1. TECHNICAL BID-COVER-A:

The Bidder should submit the Technical Bid online. The Bidder shall submit a checklist of documents enclosed with page no. in the enclosed proforma in **Format - I.**

The following shall constitute Technical Bid:

5.1.1. Description of Bidder & Details viz. Name and address etc of the laboratory in proforma enclosed **:** Should include the information asked in **(Format – II).**

5.1.2. Copy of e-Transfer Receipt for submission of tender processing fee along with **Format – III**

5.1.3. Copy of e-Transfer Receipt for submission EMD with **Format - IV**/ Copy of exemption certificate

5.1.4. Notarized Photocopy of Analytical Laboratory License valid on the date of submission of tender and a validity certificate issued by the concerned State Drug Licensing Authority **(Annexure-II).**

5.1.5. Notarized photocopy of NABL Accreditation **(Annexure-.III).**

5.1.6. Notarized photocopy of scope approved by NABL and List of Pharmaceutical Formulations for which accreditation is available**. (Annexure-IV).**

5.1.7. Notarized photocopy of GST (Goods & Services Tax) registration certificate **(Annexure – V).**

5.1.8. Notarized photocopy of GLP (Good Laboratory Practice) Certificate issued by the State Drug Licensing Authority **(Annexure-VI).**

5.1.9. Experience Certificate of Analysis of Drugs **(Annexure – X)**

5.1.10. The list of qualified personnel employed in the laboratory on the enclosed proforma **(Format - X).**

5.1.11. The list of sophisticated instruments and Equipments available (Numbers) in the laboratory with make, model, date of installation and last calibration date on the proforma enclosed as **(Format – XI).**

5.1.12. Microbiological testing facilities available in the laboratory on the proforma enclosed as **(Format –XII).**

5.1.13. A declaration in the prescribed proforma duly signed for the acceptance of The tender conditions (As per **Format –XIII**) .

5.1.14. The details of Drugs, (along with item code) quoted for analysis should be given in **Annexure XI (EDL), XII** (**Non - EDL Drug List) & XIII (Diagnostic Kits).**

(Please note that this list should not mention the testing charges).

5.1.15. Details of the Name, Address, Telephone Number, e-mail address of the Managing Director, Partners, Proprietor of the Analytical laboratory should be provided on proforma enclosed **(Format–XV).** As documentary evidence for the constitution of the Company/firm such as Memorandum and Articles of Association/ partnership deed (notarised) etc. should be submitted. The Government Laboratories and laboratories of educational institutions of repute shall submit Name, address, telephone number, fax number and e-mail address of the person-in-charge of the laboratory.

5.1.16. List of Clientele of the laboratory for whom they did analysis in the previous year (2023-2024) duly certified by Chartered Accountant **(Annexure –IX).**

5.1.17. Letter of Authorization (As per **Format – XVI).** Any agent will not be authorized to sign the tender documents on behalf of the Company.

5.1.18 Notarized copy of non-Conviction certificate issued by drug licensing authority /competent authority of concern state is either currently valid or Issued within 6 months prior to bid submission end date for all premises **(Annexure- VII)**

5.1.19. Average Annual turnover statement certified by the auditors for the last three years, i.e., 2021-2022, 2022-23 and 2023-24 **(** As per **Format – V) UDIN is mandatory on all financial documents.**.

5.1.20. A declaration that the Bidder has not been blacklisted/debarred by any State/Central Government Organization and that the Bidder has not been convicted by any Court of Law for violations under Drugs and Cosmetics Act and Rules thereunder **(** As per **Format – VI).**.

5.1.21. The Bidder should submit an undertaking that they will retain residual sample for six months after submission of report and agree to undertake analysis in the presence of the representative(s) of UPMSCL in case of doubt or otherwise (As per **Format - XVII)**.

5.1.22. Copy of firm's PAN card **(Annexure – VIII)**

5.1.23. Bank Details of the Bidder**. (**As per **Format – VII**)

5.1.24. Letter of authorization **(**As per **Format – XVI)**

5.1.25. Other documents for establishing eligibility of bidder

5.1.26. Any other documents if asked by TIA before last date of bid submission.

5.1.27. Proforma for Performance Statement **(Format – IX)**

Note:

i. ***The list documents mentioned above is only inclusive in nature; the bidder should upload all other documents which may be asked by the Tender Inviting Authority. All documents should be uploaded in specific template available in tender website. All documents shall be signed by the bidder and shall bear seal of the Company/firm.***

ii. ***Original documents shall be scanned and uploaded. If photocopies of documents are scanned and uploaded while filling tender, then all photocopies of given below documents MUST BE NOTARIZED. Non-notarized photocopies will not be considered for further processing of tender***.

5.2. PRICE BID (COVER-B)

5.2.1. The Price bid has to be submitted online in excel format. The bid submission date and time will be as per " e-tender Schedule".

5.2.2. The Bidder should submit Price Bid by quoting the rate of Testing Charges for the complete analysis of "**Single Sample**" of an item and not for individual test to be performed on the sample. The Bidder shall quote testing charges on the basis of all tests to be performed on the sample as per specifications mentioned.

5.2.3 Bidder have to quote the same rate in their financial bid for the same type of formulations of drugs regardless of the concentration of the ingredients of the sample. For Single Drug, example i.e. (1) Drug "A" having Strength 250 mg & 500 mg, must be quoted the same rate in financial bid. For Combination Drug, example i.e. (2) sample X, having the composition formula of { a -50mg + b-200mg + c-150 mg} and the sample Y, having the composition formula of {a-100mg + b-250 mg + c-500 mg}(here a, b & c are supposed to be the ingredients of samples) must be quoted the same rate in financial bid. If any bidder ignore it and quotes two different rates for such type of the composition formula, only the lower rate between/among them bill be accepted.

5.2.4. The **rates quoted** should be **inclusive of all taxes**. The quoted rates should be specific and should be furnished both in figures and words. In case of discrepancy between figure and words, the rates quoted in words will only be considered.

5.2.5. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the agreement period.

5.2.6. Any taxes to be deducted at source by UPMSCL at the rate fixed by the appropriate Govt. i.e. State/ Central shall be deducted at the time of payment against the services.

5.2.7. The bid submission date/time could be amended at the discretion of Tender Inviting Authority in case of technical problems. Tender Inviting Authority will not be responsible in any way for any delay.

5.2.8. Rate quoted **should be filled in downloaded BOQ of this tender and then uploaded.** (Sample BOQ indicated in **Format – XX** for reference only)

6. EVALUATION CRITERIA

6.1. Tender of the two covers submitted by each Bidder, Cover "A" (Technical Bid) Will be opened first, at the Office of Uttar Pradesh Medical Supplies Corporation Limited ,SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension, Lucknow-226002 in the presence of Bidders / Authorized representatives of the Bidders who chooses to be present After Scrutiny of the documents and the information furnished in Cover "A" and Confirmation of details stated therein, a list of eligible laboratories will be shortlisted.

6.2. Encrypted bids in e-Tendering portal shall be opened as per advertised schedule or as per the notification with digital signature of a multi-member committee authorized by MD, UPMSCL. The bids shall be evaluated by committee constituted with approval of MD, UPMSCL. Bids shall be evaluated as in compliance with the tender document.

6.3. The committee will examine the Tenders to determine whether they are complete, whether any computational errors have been made, whether required securities have been furnished, whether the documents have been properly signed stamped and whether the Tenders are generally in order. Prior to the detailed opening and evaluation of Price Tenders, the Tender Inviting Authority will determine the substantial responsiveness of each bid to the tender document. For purposes of these clauses, a substantially responsive Tender is one, which conforms to the terms and conditions of each bid to the tender documents without material deviations. Deviations from, or objections or reservations to critical provisions such as those concerning Bid Security- EMD, price bid will be deemed to be a material deviation. The Tender Inviting Authority determination of Tenders responsiveness is to be based on the contents of the tender itself without recourse to extrinsic evidence. If a Tender is not substantially responsive, it may be rejected by the Tender Inviting Authority and cannot subsequently be made responsive by the Bidder by correction of nonconformities. The tenders will be scrutinized to determine whether they are complete and meet the eligibility requirements, conditions etc. as prescribed in the Tender documents. The tenders, which do not meet the basic requirements, are liable to be treated as non – responsive and will be summarily ignored.

Note: The above mentioned aspects are descriptive and not exhaustive and a tender can be declared nonresponsive for non-fulfillment of any essential condition called out in the instant document in the considered view of the Tender Inviting Authority and the opinion of the Tender Inviting Authority shall be final and conclusive. Infirmity/Irregularity/Non-Conformity if observed during the preliminary examination, the Tender Inviting Authority find any informality and/or irregularity and/or non-conformity in a tender, the Tender Inviting Authority may waive the same provided it does not constitute material deviation /financial impact or may ask bidder to comply the same or may ask to submit documents which does not have any material deviation and financial impact and, also, does not prejudice or affect the ranking order of the bidders. Wherever necessary, the Tender Inviting Authority may convey its observation on such issues to the bidder by online web portal or website or mail etc. asking the bidder to respond by a specified date. If the bidder does not reply by the specified date or gives evasive reply without clarifying the point at issue in clear terms, that tender will be liable to be ignored / rejected.

6.4. Finalization of Analytical Laboratory

6.4.1. List of technically qualified bidders & non-qualified bidders (with reasons) shall be published as provisional list on the official website of Corporation. A window period of **2 working days** from date of publication of provisional list shall be given for submission of grievance by disqualified bidders, if any & the same shall be addressed. No representation shall be entertained after the prescribed window period. The final list of technically qualified & disqualified bidders then shall be uploaded in UPMSCL website with due approval of MD, UPMSCL.

6.4.2. Financial bid shall only be opened for the bidders who are technically qualified. If there is a discrepancy between words and figures, the rate quoted in words in financial bid shall be considered as final. In event of financial bid opening, due to provision/compulsion of e-tendering system if financial bid of the complete quoted drugs list of a bidder is opened by TIA then TIA will consider/evaluate the price bid of the bidder for the item which is technically qualified by the Technical Evaluation committee of TIA.

7. AWARD OF CONTRACTS

7.1. After complete Evaluation of tender, Rate contract for drug & diagnostic kit testing will be awarded to the qualified Bidder whose bid has been determined to be the lowest evaluated bid (L-1 rate Bidder).

7.2. **Multiple Analytical Laboratory Empanelment :** MD, UPMSCL shall have the rights to call other eligible bidders those are willing to match L-1 rates. If such analytical laboratories are found, then MD, UPMSCL/ TIA shall have right to empanel other analytical laboratories (matching L-1 rate bidder) for Drug & diagnostic kit testing.

7.3. If three Rate Contract for testing of a drug & diagnostic kits after matching with L-1 Rates i.e. L-1 Rate and two matching L-1 Rate) are not available after final financial evaluation then Tender Inviting Authority may Re -Tender for the rate contract for the testing of that particular Drug & diagnostic kit.

7.4. Qualified Analytical Laboratories will be empanelled after agreement for analysis of drugs & diagnostic kits for two years and also for rate contract for drug & diagnostic kit testing as per list of annexed drugs & diagnostic kit in the tender document..

7.5. The duration of the rate contract agreement shall initially be for a period of Two (02) years from the date of execution of the agreement or as specified in the contract commencement notice. However the validity of agreement may be extended further on mutual consent of both the parties for a period of up to six (06) months at a time, subject to a maximum cumulative extension of (01) year beyond the original agreement period..Such extension(s), if any, shall be made on the same terms, conditions, and approved rates as agreed upon in the original contract..

7.6. . Drug batch & diagnostic kit batch sample will be sent to L-1 rate bidder and matching L-1 rate bidder equally as per DVDMS Portal provision.

7.7. The Tender Inviting Authority, Uttar Pradesh Medical Supplies Corporation Limited reserves the right to accept or reject any tender for any one or more of the items tendered for, without assigning any reason.

7.8. **Alternate Drug Batch Sample Testing**

In case at any point of time, sufficient no. of Laboratories are not available then UPMSCL shall have the liberty to send the samples for testing to non-empanelled bidder laboratories who have quoted higher rates, in order of their preference , or to testing laboratories empanelled by other corporations.

***Note**: No bidder shall try to influence the Tender Inviting Authority on any matter relating to its bid, from the time of the bid opening till the time the contract is awarded. Any effort by a bidder to modify his bid or influence the TIA in the Bidder's bid evaluation, bid comparison or contract award decision shall result in the rejection of the bid.*

8. BIDDER'S RIGHT TO ACCEPT ANY BID AND TO REJECT ANY BID

The Bidder's reserves the right to accept or reject any bid, and to annul the bidding process and reject all bids, at any time prior to award of contract without assigning any reason whatsoever and without thereby incurring any liability to the affected bidder or bidders on the grounds of TIA action.

9. ISSUE OF NOTIFICATION OF AWARD

The issue of Notification of Award shall constitute the intention of the TIA to enter into contract with the bidder. The TIA shall notify the successful bidder through website notification & by e-mail (indicated in bid submitted), that its bid has been accepted. The bidder shall give his acceptance within 21 days of issue of the Notification of Award, along with agreement document in conformity with the bid document. In case the bidder is not willing to unconditionally accept the contract within the specified timeframe, the EMD submitted shall be liable to be forfeited.

The UPMSCL will reject the tenders of blacklisted laboratories, in accordance with Blacklisting Procedures for Analytical Laboratory and right to reject those whose past performance with UPMSCL is poor.

10. AGREEMENT

10.1. All Bidders who are empanelled will have to execute an agreement on a non-judicial stamp paper of value Rs. 500/-(stamp duty to be paid by the Bidder), in favour of Managing Director, Uttar Pradesh Medical Supplies Corporation Limited, Lucknow.

10.2. After complete evaluation of tender, qualified Analytical Laboratories will be empanelled after agreement for rate contract for drug & diagnostic kit testing as per list of annexed drugs &

diagnostic kit in the tender document. A written agreement shall be executed between UPMSCL & the Analytical Laboratory to whom empanelment is awarded.

10.3. Bidder has to execute the agreement (As per the **Format-XIX** for Agreement) within 21 days from the date of receipt of the intimation by Tender Inviting Authority informing that their tenders have been accepted.

10.4. If the successful Bidder fails to execute the agreement and payment of Performance security within the time specified or withdraws the tender after intimation of the acceptance of the tender has been sent or owing to any other reasons, the Bidder is unable to undertake the agreement, the empanelment will be cancelled and the Earnest Money Deposit of the Bidder shall stand forfeited. Such Bidder(s) will also be liable for all damages sustained by the Tender Inviting Authority by reasons of breach of tender conditions. Such damages shall be assessed by the Tender Inviting Authority, Uttar Pradesh Medical Supplies Corporation Limited whose decision shall be final.

11. PERFORMANCE SECURITY

11.1. The successful Bidders shall be required to pay a performance security of **Rs. 5,00,000/- (Rupees Five Lakh only)** at the time of execution of Agreement.

11.2 Performance security acts as a safeguard against unsatisfactory performance or violation of contract agreement by the supplier on the contract. Performance security shall be solicited from all successful bidders. Performance security will be furnished in form of an Account Payee **Demand Draft/FDR/BG** from a nationalized/ scheduled bank approved by RBI. Performance security is to be furnished within 21 days after notification of the award and it should remain valid for a period of **36 month's validity.** If the bidder fails to submit the performance security bond within 21 days time then penalty of 5% of performance security value will be charged. After completion of 21 days of date of issue of LOI, 30 days extra will be given with 5% penalty (nonrefundable) of PBG \ value to submit the Performance security. Failure to submit performance security within 51 days of LOI issuance date, the LOI may be cancelled by UPMSCL. This penalty shall be deducted from the EMD/subsequent payment of the supplier. In case L-2, L-3… bidders who have agreed to match L-1 price, then the performance security Deposit of L-2, L-3… bidders will be same as applicable for L-1 bidder. Payments of the supplies will ONLY be processed after receiving and confirmation of performance security bond for all the contracted suppliers.

Note: In case of breach of contract by the Analytical Laboratory, the performance security shall be forfeited. If the Analytical Laboratory duly performs and completes the contract in all respect, the performance security shall be returned to the Analytical Laboratory without any interest, on completion of all such obligations under the contract.

SECTION III

CONDITIONS OF CONTRACT

CONDITIONS OF CONTRACT

1. DEFINITIONS

- **Tender Inviting Authority (TIA**) - is the Managing Director of the UPMSCL, who on behalf of the User Institution/Government or the funding agencies invites and finalizes bids and ensures Testing of the drugs procured by UPMSCL.
- **Tender Document** - means the document published by the Tender Inviting Authority containing the data identifying the Analytical Laboratory, the drugs & diagnostic kits to be analyzed, which includes specifications, and general & specific conditions which will govern the contract on acceptance of a bid.
- **e- tender** - The process of notifying/ floating tender and pursuing actions of tender opening online.
- **Drug -** means and includes, substances defined as "Drug" in the Drugs and Cosmetics act 1940.
- **L-1 rate** - means the lowest rate declared by the Tender Inviting Authority for complete testing of drug & diagnostic kits mentioned in this Tender Document.
- **Matched L-1 rate** - means the rate of the bidder or bidders who have consented, in writing, to match with the L1 rate for the particular drug & diagnostic kit Testing and agreed to abide by the terms and conditions of the Tender Document.
- **Letter Of Intent –** is an intimation informing the successful bidder, the no. of drugs & diagnostic kit awarded for testing for which the Tender is awarded and requiring the bidder to execute agreement in the prescribed format within a specified time.
- **Empanelled laboratory** - Drug & diagnostic kit testing laboratory approved under the Drugs and Cosmetics Rules, selected by the Tender Inviting Authority after complete tender evalution for the purpose of conducting analytical testing of drugs supplied by the suppliers.

2. DIRECTIVES TO EMPANELLED LABORATORIES REGARDING COMPLETE ANALYSIS OF SAMPLES AND REPORTING :

2.1. Each Empanelled Analytical Laboratory shall be provided with a Log-in ID & Password for registering to software system DVDMS adopted by UPMSCL.

2.2. Sample of Drug & diagnostic kit batches will be sent to Analytical Laboratory by courier, after auto selection of empanelled analytical laboratories through DVDMS portal.

2.3. If any sample is received in a damaged condition by the laboratory, the sample should not be analysed and the information should be sent immediately to the UPMSCL e-mail **quality@upmsc.in**.

2.4. If any circumstances viz. break down of instrument, non-availability of reference standard etc. the Analytical Laboratory is unable to undertake the analysis of a sample, the same should be reported to UPMSCL e-mail within 24 hours of receipt of the sample and the sample should be returned to the Manager (Quality Control), UPMSCL immediately.

2.5. The analysis will be carried out as per Pharmacopoeial monographs with the use of Pharmacopoeial Reference Standards if the product sample is official in the IP, BP, USP, IHS or other recognized Pharmacopoeia For products which are not official in the current edition or the

previous edition of IP, BP, USP,IHS or other recognized Pharmacopoeia the laboratory may use methods that are validated as per ICH guidelines. The validation protocols and Master list of reference standards shall be made available for examination to the inspecting officials deputed by UPMSCL as and when required.

2.6. The analysis will be carried out on the calibrated equipments and the laboratory will provide the Master list of calibration for the examination to the inspecting officials deputed by UPMSCL as and when required.

2.7. On empanelment and entrustment of job, the Analytical Laboratory should furnish the test reports within:

2.7.1. 10 days of receipt of samples in case of Tablets, Capsules,Pessaries, ointment, Powder, External Preparations, Liquid Oral Preparations **,** Non-sterile preparations.

2.7.2. 21 days of receipt of samples in case of I.V. fluids, Small volume injectables, Eye/ear drops, Disinfectants, Items requiring microbiological testing, items requiring Sterility testing, Diagnostic Kits.

2.7.3. In case of delay from prescribed period (Above 2.7.1 and 2.7.2) in the testing, liquidated damages shall be made on the basis of following percentages of testing charges ;

(i) Delay upto 6 days (01 Day To 06 Days) of the prescribed testing period ; 2.5%

(ii) Delay exceeding 6 days (07 Days To 09 Days) of the prescribed testing period ; 5%

(iii) Delay exceeding 9 days (10 Days To 12 Days) of the prescribed testing period ; 7.5%

(iv) Delay exceeding 12 days (13 Days – 20 Days) of the prescribed testing period ; 10%

(v) Delay exceeding 20 days of the prescribed testing period; 50%

(vi) After 20 days, it is mandatory to provide test report within next 10 days (After 20 days of delay). If report will not be provided even after 10 days then sample of particular drug batch may be cancelled and Tender inviting Authority may re-send the sample to other laboratory.

(vii) If the L1 or matched supplier fails to complete the testing of drug batch sample within the stipulated timeframe, the Tender Inviting Authority reserves the right to cancel the sample. Upon such cancellation, the Authority may carry out the testing of drug batch sample through the next eligible bidder(s), as per BID ranking, or through other appropriate sources, at the risk and cost of the defaulting empanelled laboratory. After prescribed time, if such phenomenon is repeated 20 times then empanelment with particular analytical laboratory may be cancelled by Tender Inviting Authority.

Note ; The laboratory shall provide proper facilities for storage of samples so as to preserve the properties of drugs & diagnostic kit after receipt of sample from UPMSCL and their testing.

2.8. The laboratory shall retain residual sample for six months after submission of report and agree to undertake analysis in the presence of the representative(s) of UPMSCL in case of doubt or otherwise.

2.9. The results obtained in the analysis should be mentioned in figure wherever possible.

2.10. "**COMPLIES**" or "**PASS**" in the result column of the test report will be treated as **incomplete report**, if the result has some value. Every test report must have specific Opinion i.e. **Standard Quality** or **Not of Standard Quality** or **Misbranded or Spurious.**

2.11. Test reports should be printed on A 4 size paper of good quality.

2.12. The test reports shall be issued in accordance with the requirements prescribed in NABL Policy for Use of NABL Symbol/Claim of Accreditation.

2.13. All test reports should be submitted to UPMSCL in **triplicate** and test report should be uploaded in DVDMS Portal. At the time of report upload, Analytical laboratory should upload "Tax Invoice" also. In case of failure of a sample, the result must be communicated immediately to the Manager (Quality Control), UPMSCL through Phone & E-mail and test report should be sent with protocols of analysis and Spectra/chromatograms, if any.

2.14. The test report shall be issued on the format prescribed in the Drugs and Cosmetics Rules, 1945 for Analytical Laboratories but in lieu of name and address of the manufacturer, they will mention the code no. of the sample as mentioned by UPMSCL for the sample.

2.15. Quality of Testing shall be given highest priority. Managing Director/ General Manager (Quality Control), Uttar Pradesh Medical Supplies Corporation Limited or authorized representatives may inspect any empanelled laboratory, at any stage after acceptance of the Bid or Award of Contract or during the continuation of the tender and terminate / cancel its empanelment or any orders issued to the laboratory or not to entrust with any further analysis/testing to the laboratory based on facts brought out during such inspection and decisions of Managing Director, UPMSCL shall be final and binding. In event of decision for inspection, the bidders must extend full cooperation to the team to enable them to inspect.

2.16. Analytical Laboratory will carry out all the test required **(Physical, Physiochemical, ,Chemical and Biological Test)** for pharmaceutical preparation as per IP,BP,USP,IHS etc. Incomplete analysis & Incomplete Test report of any sample will not be accepted and will not be considered for payments apart from penal actions.

2.17. The Laboratory shall not, at any time, assign, sub-let or make over the present agreement or the benefits thereof or any part thereof, to any person or persons whomsoever.

3. USE OF CONTRACT DOCUMENTS AND INFORMATION

The Bidder shall not, without the TIA prior written consent, disclose the Contract, or any provision thereof, or any specification, plan, sample, or information furnished by or on behalf of the TIA in connection therewith, to any person other than a person employed by the Bidder in the performance of the Contract. Disclosure to any such employed person shall be made in confidence and shall extend only so far as may be necessary for purposes of such performance.

4. BLACKLISTING OF ANALYTICAL LABORATORY

4.1. Non performance by any Bidder with respect to empanelment conditions will disqualify a laboratory to participate in the tender of UPMSCL for maximum period of up to two years.

4.2. To assess the correctness of the test results being given by the Empanelled laboratories, at random, UPMSCL can exercise the option of witness testing by its authorized representatives from the residual sample or alternatively the remaining samples may be sent to the Government Analyst, U.P. for testing and if any variation is found the result would be informed to empanelled

laboratories. If there is any variation in the test data more than 5% in the analytical reports furnished by the empanelled laboratories (either pass or fail) with the Government Analyst, U.P. laboratory for 3 times in assay and 4 times for parameters other than assay for any drug in a year, the empanelled laboratory will be blacklisted for a maximum period of **two years** besides forfeiture of the performance security after following the due process.

4.3. If it is revealed that the Analytical Laboratory is involved in fraudulent Practices or any form of fraud and collusion with the suppliers to UPMSCL, the Analytical Laboratory will be blacklisted for maximum period of **Five years**. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned State's Drug Control department for penal action against them.

4.4. If it is found that the empanelled Laboratory has, at any time, assigned, sub-let or made over the present agreement or the benefits thereof or any part thereof, to any person or persons the Laboratory shall be blacklisted for a period of maximum period of **two years**.

5. PENALTY CLAUSE

5.1 If the successful Bidder fails to execute the agreement and payment of security deposit within the time specified (Tender document as per Clause 11.2 of Section-II ; Important Information for Bidders) or withdraws the tender after intimation of the acceptance of the tender or owing to any other reasons, the Bidder is unable to undertake the agreement, the empanelment will be cancelled and the Earnest Money Deposit deposited by the Bidder shall stand forfeited by the Uttar Pradesh Medical Supplies Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Uttar Pradesh Medical Supplies Corporation Limited, by reasons of breach of tender conditions. Such damages shall be assessed by the Tender Inviting Authority/ Managing Director, Uttar Pradesh Medical Supplies Corporation Limited whose decision shall be final.

5.2 Where there is temporary or permanent suspension/ cancellation/ withdrawal/ revoking of the statutory approval/ certification/ accreditation on the basis of which the laboratory was empanelled and contract was awarded, the contract will stand terminated from the date of such action coming into force. Such termination may, however, be withdrawn if the action is cancelled or stayed by any competent forum. It will be onus of the NABL approved Empanelled laboratory to report any such action taken against it.

5.2.1 As per Guideline of NABL (National Accreditation Board of Testing and Caliberation Laboratories) for suspension of NABL Accreditation if

5.2.1.1 The Suspension status is imposed for a maximum period of six months for the scope of accreditation and if not lifted, then accreditation will be withdrawn.

5.2.1.2 When a CAB (Conformity Assessment Body), remains in “Suspended” category for six months and has not met the condition for revoking the suspension status even after six months within valid accreditation then the accreditation will be withdrawn.

5.2.1.3 If suspension is not revoked within six months, 100% of the Performance Bank Guarantee shall be forfeited.

5.3 On empanelment and entrustment of job, the Analytical Laboratory should furnish the test reports within:

5.3.1 10 days of receipt of samples in case of Tablets, Capsules, Pessaries, Ointment, Powder, External Preparations, Liquid Oral Preparations, non-sterile Preparations.

5.3.2 21 days of receipt of samples in case of I.V. fluids, Small volume injectables, Eye/ear drops, Disinfectants, Items requiring Sterility testing, Microbiological testing, Diagnostic kit

5.3.3 In case of delay from prescribed period (Above 5.3.1 and 5.3.2) in the testing, liquidated damages shall be made on the basis of following percentages of testing charges.

5.3.3.1 Delay upto 6 days (01 Day To 06 Days) of the prescribed testing period ; 2.5%

5.3.3.2 Delay exceeding 6 days (07 Days To 09 Days) of the prescribed testing period ; 5%

5.3.3.3 Delay exceeding 9 days (10 Days To 12 Days) of the prescribed testing period ; 7.5%

5.3.3.4 Delay exceeding 12 days (13 Days – 20 Days) of the prescribed testing period ; 10%

5.3.3.5 Delay exceeding 20 days of the prescribed testing period ; 50%

5.3.3.6 After 20 days, it is mandatory to provide test report within next 10 days (After 20 days of delay). If report will not be provided even after 10 days then sample of particular drug batch will be cancelled and Tender inviting Authority may re-send the sample to other laboratory.

5.3.3.7 If the L1 or matched supplier fails to complete the testing of drug batch sample within the stipulated timeframe, the Tender Inviting Authority reserves the right to cancel the sample. Upon such cancellation, the Authority may carry out the testing of drug batch sample through the next eligible bidder(s), as per BID ranking, or through other appropriate sources, at the risk and cost of the defaulting empanelled laboratory. After prescribed time, if such phenomenon is repeated 20 times then empanelment with particular analytical laboratory may be cancelled by Tender Inviting Authority.

(In all the above conditions, 5.1 to 5.3, decision of the Tender Inviting Authority shall be final and binding.)

6. PAYMENT TERMS

6.1. No advance payment towards any analysis will be made to the empanelled Bidder.

6.2. No payment will be made for the incomplete analysis or incomplete report.

6.3. Payments towards the analysis of drugs and other items will be made as per rates approved along with taxes applicable at the time of payment and strictly as per rules of the Uttar Pradesh Medical Supplies Corporation Limited.

6.4. Payment will be made centrally by the Tender Inviting Authority of UPMSCL by RTGS/ NEFT into the account of empanelled laboratory.

6.5. The payment shall be released after receipt of claim from laboratory upon submission of Test Reports for the samples tested and soft copy of related spectra/chromatograms, if any.

6.6. All bills/invoices should be raised in duplicate in the name of the Managing Director, Uttar Pradesh Medical Supplies Corporation Limited.

7. PRICES

7.1. Prices charged by the Analytical Laboratory for Drug batch or diagnostic kit batch testing shall not be higher than the prices quoted by the Analytical Laboratory in his BID.

7.2. In the case of revision of Statutory Levies/Taxes during the finalization period of tender, the TIA reserves the right to ask for reduction in the prices.

7.3. Prices once fixed will remain valid during the entire empanelled period. Increase of Taxes and other statutory duties will not affect the price during this period.

7.4. Any increase in taxes and other statutory duties/levies after the expiry of the delivery date shall be to the Analytical Laboratory's account. However, benefit of any decrease in these taxes/duties shall be passed on to the UPMSCL's account by the bidder laboratories.

7.5. In case the Bidder intends to Test the Drugs under contract with UPMSCL to any other organization at a price/rate lower than the contract rate with UPMSCL then the same would be intimated promptly and contract rate would be revised accordingly.

8. FORCE MAJEURE

8.1. For purposes of this clause, Force Majeure means an event beyond the control of the successful bidder and not involving the successful bidder's fault or negligence and which is not foreseeable and not brought about at the instance of, the party claiming to be affected by such event and which has caused the non – performance or delay in performance. Such events may include, but are not restricted to, acts of the Tender Inviting Authority either in its sovereign or contractual capacity, wars or revolutions, hostility, acts of public enemy, civil commotion, sabotage, fires, floods, explosions, epidemics, quarantine restrictions, strikes excluding by its employees, lockouts excluding by its management, and freight embargoes. **Scarcity of testing materials and power cut shall not be considered as force majeure.**

8.2. The successful bidder shall not be liable for forfeiture of its performance security, liquidated damages or termination for default, if and to the extent that, it's delay in performance or other failure to perform its obligations under the Contract is the result of an event of Force Majeure.

8.3. If a Force Majeure situation arises, the Bidder shall promptly notify the TIA in writing of such a condition and the cause thereof with satisfactory documentary proof, within twenty-one (21) days of occurrence of such event. The time for testing of samples may be extended by the Tender Inviting Authority at its discretion for such period as may be considered reasonable. Unless otherwise directed by the TIA in writing, the Bidder shall continue to perform its obligations under the Contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the Force Majeure event. In case Force Majeure event the Tender Inviting Authority is unable to fulfill its contractual commitment and responsibility, the Tender Inviting Authority will notify the successful bidder accordingly.

9. RECOVERY OF DUES TO THE UPMSCL, FROM THE LABORATORY

9.1. All expenses, damages and other dues payable to the UPMSCL by the Laboratory under any provisions of this Agreement may be recovered from the amounts due or subsequently

becoming due from the UPMSCL to the Laboratory under this or any other Agreement. In case such amounts are insufficient to fully cover such expenses, damages or other dues payable, it shall be lawful for the UPMSCL to recover the balance amount from the Performance Security of the Laboratory and all other money held by UPMSCL, and in such case if Performance Security is insufficient, then it shall also be lawful for the UPMSCL to recover the residue of the said expenses, damages and dues, if necessary, by resorting to legal proceedings against the Laboratory.

9.2. In all matters pertaining to the tender, the decision of The Tender Inviting Authority/Managing Director, Uttar Pradesh Medical Supplies Corporation Limited, shall be final and binding.

10. TERMINATION OF AGREEMENT ON BREACH OF CONDITIONS:

10.1. In case the Laboratory fails or neglects or refuses to faithfully perform any of the Covenants on its part herein contained or violates the condition in Tender Document, it shall be lawful for the UPMSCL to forfeit the amount deposited by the Laboratory as Performance Security and cancel the agreement, apart from blacklisting the Laboratory for a period of up to two years.

10.2. In case the Laboratory fails, or refuses to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulations and provisions herein contained, it shall be lawful for the UPMSCL on any such failure, neglect or refusal, to put an end to the Agreement and thereupon every article, clause and thing herein contained on the part of the UPMSCL shall cease and be void, and in case of any damage, loss, expense, differences in cost or other money during the continuance of the Agreement becoming due or owing by the Laboratory to the UPMSCL, it will be open for the UPMSCL to recover from the Laboratory, all such damages, losses, expenses, differences in cost or other dues as aforesaid, it shall be lawful for the UPMSCL to appropriate the Performance Security made by the Laboratory as herein before mentioned to reimburse all such damages, losses, expenses, differences in cost and other dues as the UPMSCL shall have sustained, incurred or been put to by reason of the Laboratory having seen quality of any such failure, negligence or refusal as aforesaid or other breach in the performance of the Agreement.

10.3. At any time during the period of the agreement, if it is found that any information furnished by the Laboratory to the UPMSCL, either in its Tender or otherwise, is false, UPMSCL, may put an end to the Agreement/ Agreement wholly or in part.

10.4. The Laboratory will not be entitled for any compensation whatsoever in respect of termination of the Agreement by the UPMSCL.

11. TERMINATION FOR INSOLVENCY

The Tender inviting Authority may at any time terminate the Contract in its entirety, if at any time, the successful bidder files for insolvency in any court or agency pursuant to statute or regulation of any state or country. Tender inviting Authority shall give written notice to the successful bidder, if the Supplier becomes bankrupt or otherwise insolvent. In this event, termination shall be without

compensation to the Bidder, provided that such termination shall not prejudice or affect any right of action or remedy that has accrued or shall accrue thereafter to the Tender inviting Authority.

12. TERMINATION FOR CONVENIENCE

The Tender inviting Authority, may by written notice sent to the Bidder, may terminate the Contract, in whole or in part, at any time for its convenience. The notice of termination shall specify that termination is for the TIA convenience, the extent to which performance of work under the Contract is terminated, and the date upon which such termination becomes effective.

13. RESOLUTION OF DISPUTES

13.1. If dispute or difference of any kind shall arise between the Tender Inviting Authority and the successful bidder in connection with or relating to the contract, the parties shall make every effort to resolve the same amicably by mutual consultations.

13.2. If, after thirty (30) days from the commencement of such informal negotiations, the TIA and the Bidder have been unable to resolve amicably a Contract dispute, either the Tender Inviting Authority or the successful bidder may give notice to the other party of its intention to commence arbitration, as provided by the applicable arbitration procedure and shall be as per the Arbitration and Conciliation Act, 1996.

13.3. In the case of a dispute or difference arising between the Tender Inviting Authority and a bidder relating to any matter arising out of or connected with the contract, such dispute or difference shall be referred to a sole arbitratoror as mutually decided by the parties. The fees, if any, for the arbitration including arbitrator fees, if required to be paid before the award is made and published, shall be borne equally by both parties. The Arbitrator's award shall be final and Conclusive.

13.4. **Seat of Arbitration**: The seat of arbitration shall be at Lucknow, Uttar Pradesh, India. Courts of Lucknow shall have exclusive jurisdiction.

13.5. The language of Arbitration shall be English language and shall be governed, construed in accordance with applicable Indian laws.

14. GOVERNING LANGUAGE

The contract shall be written in English language. All correspondence and documents pertaining to the Contract which are exchanged by the parties shall be written in the same language.

15. NOTICES

For the purpose of all notices, the following shall be the address of the **Tender Inviting Authority.**

UTTAR PRADESH MEDICAL SUPPLIES CORPORATION LIMITED

(A Government of Uttar Pradesh Undertaking)

Regd. Office: **SUDA Bhawan , 7/23, Sector-7, Gomti Nagar Extension, Lucknow-226002**

Tel. No.- 0522-2838102

E-mail- quality@upmsc.in

16. FRAUDULENT AND CORRUPT PRACTICES

It is required that all concerned namely the bidders/ Successful bidders etc to observe the highest standard of ethics during the empanelment, Drug testing and execution of such contracts. In pursuance of this policy, the Tender Inviting Authority defines, for the purposes of this provision, the terms set forth below as follows:

16.1. "**Corrupt practice**" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;

16.2. "**Fraudulent practice**" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation; shall also include misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of the Tender Inviting Authority, and includes collusive practice among bidders (prior to or after tender submission) designed to establish tender prices at artificial non-competitive levels and to deprive the Tender Inviting Authority of the benefits of free and open competition. Suppression of facts such as blacklisting of the product/bidder elsewhere for reason of failure in quality / conviction under Drugs and Cosmetics Act/submission of fake/forged document shall be deemed as fraudulent practices. Making false/incorrect statement shall also be treated as fraudulent practice.

16.3. "**Collusive practice**" is an arrangement between two or more parties designed to achieve an improper purpose, including influencing improperly the actions of another party;

16.4. "**Coercive practice**" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;

16.5. "**Obstructive practice**" is deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a Tender inviting authority investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation.

16.6. No bidder shall contact the Tender Inviting Authority or any of its officers or any officers of the Government on any matter relating to its bid, other than communications for clarifications and requirements under this tender in writing, with an intention to influence the members of various committees or officials of Tender Inviting Authority or any person associated with UPMSCL. Any such effort by a bidder to influence the Tender Inviting Authority/ Analytical inspection team/ sample evaluation committee/ bid comparison or contract award decisions may result in rejection of the bid; or If the TIA determines at any point of time that the Bidder/Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the TIA may reject the bid submitted by the bidder or terminate the contract of supplier.

17. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against Tender Inviting Authority or any person under UPMSCL for anything that is done in good faith or intended to be done in pursuance of this tender.

18. FALL CLAUSE

The prices under a rate contract shall be subject to price fall clause. If the rate contract holder quotes/ reduces its price to render similar goods, works or services at a price lower than the rate contract price to anyone in the State at any time during the currency of the rate contract, the rate contract price shall be automatically reduced with effect from the date of reducing or quoting lower price, the rate contract shall be amended accordingly. The firms holding parallel rate contracts shall also be given opportunity to reduce their price by notifying them the reduced price giving them fifteen days time to intimate their acceptance to the revised price. Similarly, if a parallel rate contract holding firm reduces its price during currency of the rate contract, its reduced price shall be conveyed to other parallel rate contract holding firms and the original rate contract holding firm for corresponding reduction in their prices. If any rate contract holding firm does not agree to the reduced price, further transaction with it, shall not be conducted.

SECTION IV

FORMATS

FORMATS

FORMAT – I

CHECK LIST

The bidders are hereby instructed to upload the following documents as per the checklist and must mention the page numbers against each column of the checklist. The documents should be page numbered & arranged serially, self-attested, stamped by the authorized signatory and attested by public notary.

Checklist sheet is mandatory to fill & the documents of technical bid should be arranged in accordance to checklist

S. No.	Description of the document	Yes/No	Page no.	Remarks
1	Checklist of Document enclosed as per **Format – I**			
2	Description of the Analytical Laboratory: Should include the information asked in **Format – II**			
3	Copy of e-Transfer Receipt for deposit of tender processing fee along with **Format – III**			
4	Copy of e-Transfer Receipt for deposit of EMD along with **Format – IV** / Copy of exemption certificate.			
5	Notarized Photocopy of Analytical Laboratory License			
6-	Notarized Photocopy of NABL Accreditation Certificate			
7-	Scope Approved by NABL and List of pharmaceutical formulation for which accreditation is available			
8-	List of pharmaceutical formulations for which laboratory has NABL accreditation as per **Format-XIV**			
9-	Three years experience of analysis			
10-	Notarize Photocopy of GST registration certificate.			
11-	Notarize Photocopy of & GLP certificates issued by State Drug Licensing Authority			
12-	Non- Conviction certificate issued by licensing authority (issued within 6 months prior to opening of the tender) for all premises.			
13-	Average annual turnover statement (**Format – V**) along with audited balance sheet.(UDIN No. is mandatory)			
14-	Declaration as per **Format-VI**			
15-	Bank Details of the bidder. (As per **Format – VII**)			
16-	Bank Guarantee Format for Performance Security as per **Format-VIII**			

17-	Copy of Laboratory PAN card.			
18-	Performa for performance Statement as per **Format-IX**			
19-	List of Personnel involved in analysis as per **Format-X**			
20-	List of Sophisticated instrument/apparatus available in Laboratory as per **Format-XI**			
21-	Facilities in microbiological testing section as per **Format-XII**			
22-	A Declaration on the Prescribed Proforma Duly Signed for the Acceptance of the Tender Conditions as per **Format-XIII**			
23-	Details of Directors/Partners/Proprietor etc as per **Format-XV**			
24-	Letter of Authorization as per **Format-XVI**			
25-	Undertaking of Retaining Residual Samples up to 6 Months of submission of Test Reports & Reanalysis as per **Format-XVII**			
26-	List of Clientele of Laboratory for whom they did Analysis in the previous year (2023-2024) duly certified by Chartered Accountant			
27-	Pre Contract Integrity Pact as per **Format-XVIII**			
28-	Agreement for the Empanelment of Analytical Laboratory as per **Format-XIX**			
29-	EDL Drugs (Quoted / Non Quoted) **(Annexure – XI)**			
30-	List of Non EDL Drugs (Quoted / Non Quoted) **(Annexure – XII)**			
31-	List of Diagnostic Kits 9Quoted/Non-Quoted) **(Annexure – XIII)**			
32-	Standard operating procedure as per **Format -XXII**			
33-	Quality checks over the Labs as per **Format- XXI**			
34-	Other documents for establishing eligibility of bidder			
35-	Other document if asked by TIA			

Note : BOQ/Price bid has to be uploaded in the specific template in tender portal and shall not be included as part of the technical bid. Integrity pact & Agreement are not required to be submitted as part of the bid as the same would be required to be furnished by qualified bidders to whom contracts shall be awarded.

Format – II

Details Of Analytical Laboratory

S.N.	Particulars	Details
1-	Name of Laboratory	
2 -	Full Address	
3-	CIN	
4 -	Name & Contact details of Owner/Managing Director of the Company	
5 -	Phone No./Mobile	
6 -	e-mail	
7 -	Branches & Their Addresses	
8 -	Date of Inception	
9 -	License No. & Date of Issue	
10 -	License Issued By	
11 -	Validity of License	
12 -	Details of Manufacturing activity if any	
13 -	Name & Designation of the person authorizing	
14 -	Name, Designation & Contact details of the Authorized signatory submitting bid & signing contract	
15 -	Specimen Signature of Authorized signatory	
16-	Name of the In-charge of the Laboratory with Contact No.	
17 -	Specimen Signature of the officer who is authorized to sign the Test reports	
18-	GST No.	
19-	PAN No.	

Note : All correspondence to the Laboratory will be done on (5) & (6) only.

Format – III

PARTICULARS OF TENDER FEE DEPOSITED
(To be submitted along with technical bid)

i) **Reference No. of BID :**

ii) **Particulars of Tender fee : -**

a) NEFT /e- Transfer Reference No. _____

b) Date on which transfer made_____

c) Transferred Amount Rs. ---------- only.

d) Name and address of Bank through which transfer made ----------

e) Name and address of the bidder:

iii) PAN No:
(Copy of PAN card duly attested by the bidder under his seal and signature to be submitted.)

iv) GST No:
(Copy of GST certificate duly attested by the bidder under his seal and signature to be submitted)

_____
SIGNATURE OF THE AUTHORIZED REPRESENTATIVE

NAME_____

DESIGNATION_____

NAME OF THE FIRM/ BIDDER_____

STAMP OF THE FIRM/ BIDDER _____

Format – IV

PARTICULARS OF EMD DEPOSITED
(To be submitted along with technical bid)

i. Reference No. of Bid:

ii. Particulars of EMD submitted: -

iii. RTGS/e- Transfer Reference No. _____

iv. Date on which transfer made_____

v. Transferred Amount Rs.---------- only (Rupees……..……only).

vi. Name and address of Bank through which transfer made ----------

vii. Name and address of the bidder:

viii. PAN No:

ix. (Copy of PAN card duly attested by the bidder under his seal and signature to be submitted.)

x. GST No:

xi. (Copy of GST certificate duly attested by the bidder under his seal and signature to be submitted)

_____
SIGNATURE OF THE AUTHORIZED REPRESENTATIVE

NAME_____

DESIGNATION_____

NAME OF THE FIRM/BIDDER_____

Format – V

AVERAGE ANNUAL TURNOVER CERTIFICATE

To

Managing Director,
UP Medical Supplies Corporation Ltd.
SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension,
Lucknow, Uttar Pradesh-226002

We hereby certify that **M/s**_____ (the name of participant in the tender) who is participating the tender for the empanelment of Analytical Testing Laboratories for the analysis of Drugs and Diagnostic Kits, called by UPMSCL, Lucknow, vide Tender reference number UPMSCL/QC-006/ 011 /25-26 has a Financial turnover given as below: -

(1)	Turnover in the Financial Year 2021-2022.	Rs.
(2)	Turnover in the Financial Year 2022-2023.	Rs.
(3)	Turnover in the Financial Year 2023-2024.	Rs.

The above information is correct and true.

Office seal:

Signature
Name of Proprietor / Partner/Authorized Signatory of
bidder with firm's rubber stamp/seal

CERTIFIED BY CHARTERED ACCOUNTANT (CA)

Name of Chartered Accountant (In capital letter):
Regd. No. of Chartered Accountant:_____
UDIN (Unique Document Identification Number) :

NOTE : The turnover of other than participant will not be accepted. Audited balance sheet & profit & loss statement for above mentioned three years (Self attested & Certified by CA shall also be enclosed as proof of the claim). **UDIN** is **mandatory and it should be mentioned on each financial Statement.**

FORMAT - VI

'Notarized on Rs. 100/- Non Judicial stamp paper'

DECLARATION

PHOTO

I,……S/o……

R/o……

….do solemnly affirm:

That my Firm/Company/Corporation/LLP is participating in tender no. UPMSCL/QC-006/011/25-26 of MD, Uttar Pradesh Medical Supplies Corporation Ltd., Lucknow and I am executing this declaration for myself and on behalf of my Firm/Company/Corporation/LLP.

1. That my Firm/Company/Corporation/LLP and it's Proprietor or any of its Directors/Partners/Authorized signatories has not been convicted under the provisions of Drugs and Cosmetics Act and Rules there under, Drug (Prices Control) Order or any other law related to drugs by any Court of India. I shall inform the UPMSCL immediately, if there is any conviction from aforesaid any authority.
2. That my Firm/Company/Corporation/LLP is not under blacklisting/ debarring by any Tender Inviting Authority, UPMSCL for any reason or by Central Govt./any State Govt. or organizations/agencies there under on grounds of Drug Quality/Regulatory non compliance issues.
3. In case of exemption of my Firm/Company/Corporation/LLP from payment of Earnest Money Deposit by a Govt. order, I undertake to pay the said sum without any demur on receipt of demand issued by the Tender Inviting Authority.
4. That, the rates quoted are not higher than the rates quoted to other Government/Semi-Government/Autonomous/Public Sector Hospitals/ Institutions/ Organizations situated in India in the same financial year and also not higher than the prices notified by the Competent authority. In case my firm/company/Corporation/LLP decides to test same drugs at lower prices, to Central Govt. or any State Government or their organizations/agencies, the same will be intimated to UPMSCL immediately and the contract shall be revised accordingly.
5. That the information given by me in this tender form is true and correct to the best of my knowledge and belief and I am aware of the 'Tender Inviting Authority's' right to forfeit the Earnest Money Deposit and/or Security Deposit and blacklist my Firm/Company/Corporation/LLP, if any information furnished is proved false.
6. That I have read the terms and conditions of the tender and I and my firm/Company/Corporation/LLP agree to abide by these terms and conditions and other guidelines issued in this regard.

DATE: **Signature:**

Name:

Designation:

SEAL:

Note: Letter of Authorization to sign the tender document/related papers/deeds are to be enclosed with this undertaking.

FORMAT – VII

BANK DETAILS OF THE BIDDER

1	**Name of the Bank.**	
2	**Branch Name& address.**	
3	**Branch Code No.**	
4	**Branch Manager Mobile No.**	
5	**Branch Telephone no.**	
6	**Branch E-mail ID**	
7	**9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank**	
8	**IFSC code of the Branch**	
9	**Type of Account (Current/Saving)**	
10	**Account Number (As per in cheque book)**	

(in lieu of the bank certificate to be obtained, please **attach the copy of original cancelled cheque** issued by bank for verification of the above particulars).

I /We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all for reasons of incomplete or incorrect information, I shall not hold M/s. Uttar Pradesh Medical Supplies Corporation Ltd. (UPMSCL) responsible. I have read the conditions of the tender/agreement entered and agree to discharge the responsibility expected of me / from the company as a bidder /successful bidder.

Date: Company Seal Signature

Place: (Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Bank Seal with address. Signature of the authorized official of the bank.

FORMAT-VIII

Bank Guarantee Format for Performance Security

To,
The Managing Director,
Uttar Pradesh Medical Supplies Corporation Ltd.
SUDA Bhawan, 7/23, Sector-7, Gomti Nagar Extension,
Lucknow, Uttar Pradesh

WHEREAS ..…….... (name and address of the Bidder) (hereinafter called “Analytical Laboratory”)
has undertaken, in pursuance of contract no……. dated ……. to Drug Analysis (description of drug List) & Diagnostic Kit (description of diagnostic kit List) herein after called “the contract”).
AND WHEREAS it has been stipulated by UPMSCL in the said contract that the supplier shall furnish you with a bank guarantee by a scheduled commercial bank recognized by you for the sum specified therein as security for compliance with its obligations in accordance with the contract;

AND WHEREAS we have agreed to give the Analytical Laboratory such a bank guarantee;
NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, on behalf of the Analytical Laboratory, up to a total of……. (amount of the guarantee in words and figures), and we undertake to pay you, upon your first written demand declaring the Analytical Laboratory to be in default under the contract and without cavil or argument, any sum or sums within the limits of (amount of guarantee) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.
We hereby waive the necessity of your demanding the said debt from the Analytical Laboratory before presenting us with the demand.
We further agree that no change or addition to or other modification of the terms of the contract to be performed thereunder or of any of the contract documents which may be made between UPMSCL and the Analytical Laboratory shall in any way release us from any liability under this guarantee and we hereby waive notice of any such change, addition or modification.

This guarantee shall be valid until the ……..... day of ……..……, 2025.
…….

(Signature of the authorized officer of the Bank)
…….

Name and designation of the officer

…….
Seal, name and address of the Bank / Branch

Format- IX

Proforma for Performance Statement

(For a period of last 3 years)

Name & Address of the Laboratory : _____

S.No.	Types of Samples Analysed	NO. OF SAMPLES ANALYSED		
		Year 2021-2022	Year 2022-2023	Year 2023-2024
1.	Capsule			
2.	Chewing Gum			
3.	Cream			
4.	Disinfectant fluid			
5.	Eye drop			
6.	Ear drop			
7.	Enema			
8.	Eye Ointment			
9.	Gel			
10.	Injectables			
11.	Inhalational Powder			
12.	Inhalational Liquid			
13.	Insecticidal Liquid			
14.	Insecticidal Powder			
15.	Larvicidal Liquid			
16.	Lotion			
17.	Nasal drop			
18.	Ointment			
19.	Oral Powder			
20.	Oral Solution/ Syrup/ Suspension			
21.	Pessaries			
22.	Powder			
23.	Powder for injection			
24.	Suppositories			
25.	Tablet			
26.	Topical Solutions			
27.	Transdermal Patch			
28.	Diagnostic Kit			

Signature of Authorised Signatory……..

Office Seal :

Format- X

LIST OF PERSONNEL INVOLVED IN ANALYSIS

S.No.	Name of Analyst	Designation	Qualification	Analytical Experience	Whether approved for analysis by the Drug Licensing Authority
1.					
2.					
3.					
4.					
5.					

:

Signature:-…….

Date:-……

Name or Lab:-…….

Office Seal:-…….

Format- XI

LIST OF SOPHISTICATED EQUIPMENT/ APPARATUS AVAILABLE IN THE LABORATORY

S.No.	Name of Equipment	No. of equipment	Date of Installation	Date of last calibration	Working Condition

Signature :
Date :
Name of Lab. :

Office Seal :

Format- XII

FACILITIES IN THE MICROBIOLOGICAL TESTING SECTION

S.No.	Name of standard culture/equipment	No. of equipment	Date of Installation	Working Condition

:

Signature :
Date :
Name of Lab. :

Office Seal :

Format- XIII

DECLARATION FORM

I / We _____(Name of the Bidder) having our office at _____

Laboratory at ---------- do declare that I/We have carefully read all the conditions of tender of Uttar Pradesh Medical Supplies Corporation Limited, for the tenders floated for empanelment of analytical testing laboratories for the analysis of drugs & diagnostic kits for the tender period of Two year from the date of acceptance and abide by all conditions set forth therein.

I / We further declare that I / We posses valid License for Analytical Testing Laboratory bearing No…….which is valid upto…….

Signature :
Date :
Name of Lab. :

Office Seal :

Format-XIV

LIST OF PHARMACEUTICALS FORMULATIONS FOR WHICH LABORATORY HAS NABL ACCREDITATION

(Please enclose Specific tender scope approved by NABL in support of this list)

S.N.	Pharmaceutical Formulations	Test method specification accreditated (IP, BP, USP,IHS specify)	If accreditation available mention YES against the Pharmaceutical Preparations
1	Capsule		
2	Chewing Gum		
3	Cream		
4	Disinfectant fluid		
5	Eye drop		
6	Enema		
7	Ear drop		
8	Eye Ointment		
9	Gel		
10	Injectables		
11	Inhalational Powder		
12	Inhalational Liquid		
13	Insecticidal Liquid		
14	Insecticidal Powder		
15	Larvicidal Liquid		
16	Lotion		
17	Nasal drop		
18	Ointment		
19	Oral Powder		
20	Oral Solution/ Syrup/ Suspension		
21	Pessaries		
22	Powder		
23	Powder for injection		
24	Suppositories		
25	Tablet		
26	Topical Solutions		
27	Transdermal Patch		
28	Diagnostic Kit		

Format-XV

DETAILS OF DIRECTORS /PARTNERS /PROPRIETOR ETC.

S.No.	Name	Whether Director/ Partner or Proprietor/ Incharge of Laboratory	Whether responsible for day to day working of the Analytical Laboratory	Address	Phone no., Mobile No., E mail
1.					Ph : Mobile : E-mail :
2.					Ph : Mobile : E-mail :
3.					Ph : Mobile : E-mail :
4.					Ph : Mobile : E-mail :
5.					Ph : Mobile : E-mail :

Signature :
Date :
Name of Lab.: :
Office :

Format- XVI

Letter of Authorization

POWER OF ATTORNEY FOR SIGNING OF BID

Know all men by these presents, We, _____(name of the firm/company/LLP and address of the registered office) do hereby irrevocably constitute, nominate, appoint and authorize Mr._____/ Ms _____(Name), son/daughter/wife of _____and presently residing at _____, who is presently employed with us/ the Lead Member of our Consortium and holding the position of_____,) as our true and lawful attorney (hereinafter referred to as the **"Attorney")** to do in our name and on our behalf, all such acts, deeds and things as are necessary or required in connection with or incidental hereto submission of our bid for E-Tender for the empanelment of analytical testing laboratories for the analysis of drugs & diagnostic kits, in Uttar Pradesh Medical Supplies Corporation Limited (the "Authority") including but not limited to signing and submission of all applications, bids and other documents and writings, participate in bidders' meetings and other conferences and providing information/responses to the Authority, representing us in all matters before the Authority, signing and execution of all contracts including but not limited to the Agreements and undertakings consequent to acceptance of our bid, and generally dealing with the Authority in all matters in connection with or relating to or arising out of our bid for the procurement of drugs. We hereby ratify and confirm all acts, deeds and things lawfully done or caused to be done by our said Attorney pursuant to and in exercise of the powers conferred by this Power of Attorney and that all acts, deeds and things done by our said Attorney in exercise of the powers hereby conferred shall always be deemed to have been done by us.

IN WITNESS WHEREOF WE,_____, THE ABOVE NAMED PRINCIPAL HAVE EXECUTED THIS POWER OF ATTORNEY ON THIS DAY OF _____, 2025.

For

……

(Signature)

Witnesses:

(Name, Title and Address)

1.

2.

[Notarised]
Accepted

……

(Signature)

(Name, Title, all relevant Contact details and Address of the Attorney)

Notes :

- *The mode of execution of the Power of Attorney should be in accordance with the procedure, if any, laid down by the applicable law and the charter documents of the executants(s) and when it is so required, the same should be under common seal affixed in accordance with the required procedure.*
- *Also, wherever required, the Bidder should submit for verification the extract of the charter documents and documents such as a resolution/ power of attorney in favour of the person executing this Power of Attorney for the delegation of power hereunder on behalf of the Bidder.*
- *Power of Attorney should be executed on a non judicial stamp paper of appropriate value as relevant to the place of execution (if required under applicable laws).*
- *For a Power of Attorney executed and issued overseas, the document will also have to be legalized by the Indian Embassy and notarized in the jurisdiction where the Power of Attorney is being issued.*

Format- XVII

UNDERTAKING

I / We .....(Name of the Bidder) having our office at.....

Laboratory at ..... give this undertaking that I/We will retain residual samples after its testing upto six months of submission of test reports to UPMSCL and will undertake reanalysis of the samples in the presence of representative(s) of UPMSCL in case of doubt or otherwise.

Signature :
Date :
Name of Lab.: :

Office Seal :

FORMAT – XVIII

INTEGRITY PACT

(To be given on letter head of the Analytical Laboratory/bidder, as the case may be, duly signed by the authority having legal power of attorney to bind the firm/company)

1. This Integrity pact is a fidelity agreement between the Bidder/Analytical Laboratory (which include all their employees, agents and consultants etc. who are registered/seek registration or awarded/seek Contract(s)/Rate Contract(s) (RCs) on one hand and **Uttar Pradesh Medical Supplies Corporation Ltd** (hereinafter called UPMSCL) which includes all its employees/officials.
2. Under this Integrity Pact, it has been agreed, accepted and undertaken to use, practice and observe all the best, clean, ethical, honest and legal means and behavior maintaining complete transparency and fairness in all activities concerning Registration, Bidding, Contracting/Rate Contracting and performance thereto. Neither the Bidder nor the Public Authority which include indenters, MD,UPMSCL/Tender inviting authority and inspection officials of UPMSCL shall have conflict of interest of any kind whatsoever nor demand or pay or accept any illicit gratification/bribe or hospitality or consideration/favor of any kind whatsoever and shall not use any corrupt practices including fraud, misrepresentation, misleading or forged/false documents, concealing/suppressing facts, undue pressures or influences from anyone (written or verbal/telephonic), bribery, rigging, cartelization, anti-competitive practices, collusion, which are not limited to, but also include the following:
   (a) Collusive bidding: Collusive bidding can take form of an agreement among Bidders to divide the market, set prices, or limit testing. It can involve 'wage fixing, kickbacks, or misrepresenting the independence of the relationship between the colluding parties'. In legal terms all acts affected by collusion are considered void.
   (b) Bid rotation: In bid-rotation scheme conspiring Bidders continue to bid, but they agree to take turns being the winning (i.e. lowest qualifying) bidder. The way in which bid-rotation agreements are implemented can vary.
   (c) Cover Bidding: Cover (also called complementary, courtesy, token or symbolic) bidding occurs when individuals or firms/companies agree to submit bids that involve at least one of the following: (1) a competitor agrees to submit a bid that is higher than the bid of the designated winner, (2) a competitor submits a bid that is known to be too high to be accepted, or (3) a competitor submits a bid that contains special terms that are known to be unacceptable to the purchaser.
   (d) Bid suppression: Bid-suppression schemes involve agreements among competitors in which one or more firms/companies agree to refrain from bidding or to withdraw a previously submitted bid so that the designated winner's bid will be accepted.
   (e) Market allocation: Competitors carve up the market and agree not to compete for certain, customers or in certain geographic areas. Competing firms/companies may, for example, allocate specific customers or types of customers to different firms/companies, so that competitors will not bid (or will submit only a cover bid) on contracts offered by a certain class of potential customers which are allocated to a specific firm/company etc.
3 The party hereby agrees that he will not indulge in any such activity and will inform UPMSCL if any such activity is on. The party further agrees that he will not give any favour, bribe, speed money and gifts directly or indirectly to any employees, officials etc. of UPMSCL and will not commit any offence in contravention of relevant IPC/Prevention of Corruption Act or any Indian law in force.
4 The party hereby agrees that while canvassing order, they will not provide any inducement of the indenter, whether directly or indirectly including cash and non cash both pre, during and post procurement action and inform the UPMSCL if any such event is unfolding for which UPMSCL on assessment of the issue will refer the matter to the concerned administrative authority.
5 In case of failure or default in terms of this Integrity Pact the UPMSCL will be subjected to actions prescribed under the applicable Law of the Land, including penal actions and prosecution, while the Supplier will bear any or a combination of following penalties:

5.1. Cancellation of Contract/Rate Contracts (RCs)

5.2. Forfeiture of all securities and performance Bank Guarantees

5.3. Refusal to grant any kind of contracts/RCs for further period of 3 (three) years

5.4. Suspension and/or banning the business dealings for period upto 3 (three) years

5.5. Any other administrative or penal actions as deemed fit.

5.6. Action under IPC/Prevention of Corruption Act and other relevant laws of the country.

6. Agreed, accepted and signed on behalf of Bidder on this day and year mentioned below and handed over to the concerned office of UPMSCL forming integral part of all the affairs and transactions with and in relation to UPMSCL.

Signature on behalf of Bidder Firm/Analytical Laboratory.....

Name and designation/capacity of signatory.....

Full address of the Bidder Firm/Analytical Laboratory.....

Seal and Stamp of the Bidder Firm/Analytical Laboratory.....

Place: ……..

Date: ……

FORMAT – XIX

AGREEMENT FOR THE EMPANELMENT OF ANALYTICAL TESTING LABORATORIES FOR THE ANALYSIS OF DRUGS and Diagnostic Kits

(Non-Judicial Stamp Rs 500)

AGREEMENT

THIS AGREEMENT is made on this..... day of ....., 2025

Between

Uttar Pradesh Medical Supplies Corporation Ltd company incorporated in the Republic of India registered under the Companies Act, 2013 and having its registered office at SUDA BHAWAN,7/23, Sector-7,Gomti Nagar Extension,Lucknow-226002 and having GST No. 09AACCU2250P1ZZ hereinafter referred as the "**MD,UPMSCL/Tender Inviting Authority**", which term shall, unless excluded by or repugnant to the subject or context, include its successors and permitted assigns, of the ONE PART:

And

…… a company/firm/corporation/LLP incorporated in the Republic of India registered under the Companies Act, 2013/1956 and having its registered office at ……, and having GST No._____hereinafter referred as the **"Analytical Laboratory"**, which term shall, unless excluded by or repugnant to the subject or context, include its successors and permitted assigns, of the OTHER PART and FINAL PART.

WHEREAS the UPMSCL has invited tenders for the e - Tender for the empanelment of analytical testing laboratories for the analysis of drugs.

TENDER No.UPMSCL/QC-006/011/25-26, Dated ; ……. The Bidder has submitted technical and Price Bids as contained in the Tender Document. The Tender Inviting Authority has finalized the tender in favour of the Analytical Laboratory for the empanelment of analytical testing laboratories for the analysis of drugs and Diagnostic kits.

NOW THIS AGREEMENT WITNESSETH AS FOLLOWS:

f) In this Agreement words and expressions shall have the same meanings as are respectively assigned to them in the Tender Document referred to.

g) The following documents shall be deemed to form and be read and construed as part of this Agreement, viz.:

2.1. All the documents submitted by the tenderer as part of Technical Bid and Price Bid;

2.2. A List of L-1 Rate (With Tax) for which Analytical Laboratory is empanelled for two years as per agreement duration.(Annexure -1)

2.3. A List of Matching L-1 Rate (With Tax) for which Analytical Laboratory is empanelled for two years as per agreement duration.(Annexure -2)

2.4. The Specifications and other quality parameters

2.5. The clarifications and amendments issued / received as part of the Tender Document

2.6. The General Conditions of Contract;

2.7. The Specific Conditions of Contract; and All other condition described in tender document;

2.8. The Analytical Laboratory offer Letter

(3) Whereas the Laboratory has agreed to undertake the analytical work of the UPMSCL, the list of Formulations, Drugs and diagnostic kits mentioned in the Tender documents attached hereto at the rates noted therein and in the manner and under the terms and conditions hereinafter mentioned.

(4) And whereas the Laboratory has deposited with the UPMSCL, a sum of Rs. 5,00,000/- (Rupees Five lakh only) as Performance Security for the due and faithful performance of this Agreement, to be forfeited in the event of Non-Performance. Now these presents witness that for carrying out the said Agreement in this behalf into execution, the Laboratory and the UPMSCL, do hereby mutually convenient, declare, agreement and agree with each other in the manner following, that is to say,

(i) After agreement Analytical Laboratories will be empanelled for analysis of drugs and Diagnostic kits for two years and also for rate contract for drug and diagnostic kits testing as per list of annexed drugs & Diagnostic kits (Annxure -1, 2 & 3 of Letter of Intent).

(ii) The term “Agreement”, wherever used in this connection, shall mean and include the terms and conditions in tender floated by the UPMSCL, for Empanelment of analytical testing laboratories for the analysis of Drugs and Diagnostic kits for a period of two years from the effective date of Agreement. The instructions to Bidder, the conditions of tender, acceptance of tender particulars hereinafter defined and all those general and special conditions mentioned in tender documents.

(iii) The Agreement is for Empanelment of Analytical Laboratories of undertaking analysis of Drugs & Diagnostic kits, by the Laboratory to the UPMSCL , of the samples specified in the tender documents attached hereto at the rates noted against each therein on the terms and conditions set forth in the Agreement.

(iv) This Agreement shall be deemed to have come into force with effect from Date ……and it shall remain in force for a period up to Date ……and The duration of the rate contract agreement shall initially be for a period of Two (02) years from the date of execution of the agreement. However the validity of agreement may be extended further on mutual consent of both the parties for a period of up to six (06) months at a time, subject to a maximum cumulative extension of (01) year beyond the original agreement period. Such extension(s), if any, shall be made on the same terms, conditions, and approved rates as agreed upon in the original contract.

(5) All disputes arising will be subject to the jurisdiction of courts in Lucknow.

Signed, Sealed and Delivered by the Said
(For the **UPMSCL**)

In the presence of witness.
WITNESS **(** For the **UPMSCL)**

Signature……

Name……

Address……

Signature…….

Name……

Address……..

Signed, Sealed and Delivered by the Said
(For the **Analytical Laboratory)**

In the presence of
WITNESS **(**For the **Analytical Laboratory)**

Signature……

Name……

Address……

Signature……..

Name……

Address……..

FORMAT – XX

SAMPLE BOQ AS VISIBLE IN e-TENDER PORTAL

SN	ITEM DESCRIPTION	ITEM CODE	QUANTITY	UNIT	BASIC PRICE PER UNIT	CGST	SGST	IGST	TOTAL AMOUNT WITHOUT TAXES	TOTAL AMOUNT WITH TAXES	TOTAL AMOUNT IN WORDS (With Tex)

Format - XXI

Standard Operating Procedures

Standard Operating Procedures shall be written in a chronological order listing different steps leading to analysis of drugs or calibration of an instruments. Below mentioned SOP shall be submitted as and when required by the "Tender Inviting Authority".

(Please write Yes/No regarding availability of document and Data)

S.N .		Details of the requirement	Yes/No
1.		Availability of SOP manuals and their periodic Review.	
2.	(i)	Sample handling and accountability	
	(ii)	Receipt identification, storage, mixing and method sampling of the test and control articles	
	(iii)	Record keeping, reporting, storage and retrieval of data	
	(iv)	Coding of different studies, handling of data including use of computerized data system	
	(v)	Operation of technical audit personnel in performing and reporting audits, inspections and final report reviews	
	(vi)	Routing inspection of cleaning maintenance testing calibration and standardization of instruments ;	
	(vii)	Action to be taken in respect of Equipment Failure	
	(viii)	Analytical data methods;	
	(ix)	Health and safety protection	
	(x)	Date handling and storage retrieval	
	(xi)	Health and safety protection	
	(xii)	Animal room preparations;	
	(xiii)	Animal care	
	(xiv)	Storage and maintenance of microbial cultures	
	(xv)	Maintenance of sterility room (i e constant maintenance and monitoring of aseptic condition room):	

S.N .		Details of the requirement	Yes/No
	(xvi)	Use and storage of reference standards	
	(xvii)	Procurement of stores and equipment	
	(xviii)	Monitoring of testing of samples:	
	(xix)	Method of retention of unexpended samples, their location, maintenance and disposal	
	(xx)	Redressal of technical complaints	
	(xxi)	Document control.	
	(xxii)	House-keeping	
	(xxiii)	Calibration manual	
	(xxiv)	Training manual	
3.		Protocols and specification archive List of all the pharmacopeias A file on patent and proprietary medicines (non-Pharmacopeia) test methods to specification prepared and validated by the manufacturer. Record of the test methods which have been submitted to the concerned Drug Control Authority.	
4.		Raw data, Date integrity and security shall be maintained Original entry must be saved and the system shall trail for all data.	
5.		Storage and archival –The residual sample shall be retained in proper storage condition for a period of 6 month after the final report.	
6.		Establishment and maintainance of procedures for the identification collection, indexing, retrieval storage, maintenance and disposal of all quality documents.	
7.		All the raw data, documentation, SOP, protocols and final reports are to be retained and there shall be archives of orderly storage and expeditious retrieval of all raw data, documentation, protocols, interim and final report.	
8.		The condition under which the original documents are stored must ensure their security and confidentiality.	
9.		Raw data on thermal paper might fad away with time, therefore, a photocopy of the thermal paper shall be retained in the archive	

Format - XXII

Quality checks over the Labs

"Standard Operating Procedures (SOP) may be requested for the areas listed below, and additional documents shall be submitted as and when required by the Tender Inviting Authority."

(Please write Yes/No regarding availability of document and Data)

S.No	Particulars	Yes/No
01.	**Proficiency Testing (PT)**	
	(i) PT participation certificates (last 12-24 months)	
	(ii) Evaluation reports from approved PT providers	
	(iii) Corrective action reports for failed PT rounds	
	(iv) Evidence of PT provider accreditation (e.g.. NAIBL)	
02.	**External Quality Assurance Services (EQAS)**	
	(i) EQAS enrolment certificate	
	(ii) Round-wise EQAS reports	
	(iii) Evidence of result submission and feedback	
	(iv) Any corrective/preventive action (CAPA) reports	
03.	**Inter-Laboratory Testing or Inter laboratory comparision (ILT/ILC)**	
(A)	**Arabic Language proficiency testing (ALPT)**	
	(i) Inter laboratory comparision and Prificiency Testing participation summary	
	(ii) Comparative analysis reports	
	(iii) Minutes of internal review meetings	
	(iv) Quarterly trend summaries (if applicable)	
(B)	**Internal Quality Control (IQC)**	
	(i) Daily 100 log books or automated reports	
	(ii) Control charts (Levey-Jennings or similar)	
	(iii) SOPs for control management	
	(iii) Corrective / preventive action (CAPA) for out-of-range controls	
(C)	**Performance Data Sheet of Analysis**	
	(i) Test-wise performance summaries	
	(ii) Error rates, repeat tasting logs	
	(iii) Turnaround time (TAT) reports	
	(iv) Analyst-wise or equipment-wise performance data	
(D)	**Redo-testing and Retain Sample Testing**	
	(i) Register/log of red(o tests with justification	
	(ii) Reports of retained sample verification	

SECTION V

ANNEXURES

ANNEXURES

S.N.	ANNEXURES	Description	Page No.
1 -	I	Preparation & Submission of e-BID	61-63
2 -	II	Notarized Photocopy of Analytical Laboratory License valid on the date of submission of Tender and a Validity Certificate issued by the concerned state Drug Licensing Authority.	-
3 -	III	Notarized Photocopy of NABL Accreditation Certificate.	-
4 -	IV	Scope approved by NABL and List of Pharmaceutical Formulations for which Accreditation is available.	-
5 -	V	Notarized Photocopy of GST (Goods & Services Tax) Registration Certificate.	-
6 -	VI	Notarized Photocopy of GLP (Good Laboratory Practice) Certificate Issued by the State Drug Licensing Authority.	-
7 -	VII	Non – Conviction Certificate issued by Licensing Authority (Issued within 6 months prior to opening of the Tender) for all premises	-
8 -	VIII	Copy of Analytical Laboratory PAN Card.	-
9 -	IX	List of Clientele of Laboratory for whom they did Analysis in the previous year (2023-2024) duly certified by Chartered Accountant.	-
10 -	X	Three year experience of analysis.	-
11 -	XI	EDL (Essential Drug List)	64-79
12 -	XII	Non – EDL (Essential Drug List)	80-84
13-	XII	Diagnostic Kits	85

ANNEXURE - I

PREPARATION & SUBMISSION OF e-BIDS

- **Documents Constituting the e-Bid**
  - The e-Bids prepared by the Bidder shall comprise the following components:
  - Technical bid
  - Price bid / BOQ
  - The Bidder shall furnish, all the documents listed in tender documents as part of Technical bid, documents establishing the qualification to perform the Contract. The documentary evidence in support of the information furnished should be submitted by the Bidder electronically in the **PDF format.**
  - It is suggested that the PDF files should be made in grayscale using the minimum readable appropriate resolution so that the size of the files is minimized for fast uploading on the e-Bid portal.

- **Format and Signing of e-Bids**
  - The Bidder shall prepare one electronic copy for the e-Bids.
  - Bidder or a person or persons duly authorized to bind the Bidder to the Contract. All the pages/ documents of the e-Bid shall also be signed manually by the person authorized to sign the e-Bids before converting them into PDF and uploading them as bidding documents.

- **Submission of e-Bids**
  - The e-Bid Submission module of e-tender portal http://etender.up.nic.in enables the Bidders to submit the e-Bid online against the e-tender published by the UPMSCL. Bid Submission can be done only from the Bid Submission start date and time till the e-Bid Submission end date and time given in the e-Bid. Bidders should start the Bid Submission process well in advance so that they can submit their e-Bid in time. The Bidders should submit their Bids considering the server time displayed in the e-tender portal. This server time is the time by which the Bid submission activity will be allowed till the permissible time on the last/end date of submission indicated in the e-tender schedule. Once the Bid submission date and time is over, the Bidders cannot submit their e-Bid. For delay in submission of e-Bids due to any reasons, the Bidders shall only be held responsible.
  - The Bidders have to follow the following instructions for submission of their e-Bids:
  - For participating in e-tender through the e-Biding system, **it is necessary for the Bidders to be the registered users of the e-tender portal** http://etender.up.nic.in. The Bidder has to register with his/her **Digital Signature Certificate (DSC)** in the e-Biding system and subsequently he/she will be allowed to carry out his/her e-Bids submission activities. Registering the Digital Signature Certificate (DSC) is a onetime activity till its validity. Before proceeding to register his/her DSC, the Bidder should first log on to the e-Biding system using the User Login option on the home page with the Login Id and Password with which he/ she has registered as enumerated in the preceding paragraph above.

- For successful registration of **DSC** on e-Procurement portal http://etender.up.nic.in the Bidder must ensure that he/she should possess Class-2/ Class-3 DSC issued by any one of certifying authorities approved by Controller of Certifying Authorities, Government of India.

- **Deadline for Submission of e-Bids**
  - E-Bids must be submitted by the Bidders on e-tender portal http://etender.up.nic.in, not later than the date and time specified in this e-tender portal document.
  - The UPMSCL May extend this deadline for submission of e-Bids by amending the e-tender document in which case all rights and obligations of the UPMSCL and Bidders previously subject to the deadline will thereafter be subject to the deadline as extended.
  - UPMSCL shall not consider any request for date-extension for e-Bid-submission on account of late downloading of e-tender by any prospective Bidder. E-Bids should be uploaded on e-tender portal http://etender.up.nic.in on or before last date and time mentioned on e-portal documents.

- **Late e-Bids**
  - The server time indicated in the Bid Management window on the e-tender portal http://etender.up.nic.in will be the time by which the e-Bids submission activity will be allowed till the permissible date and time scheduled in the e-tender. Once the e-Bids submission date and time is over, the Bidder cannot submit his/ her Bid. Bidder has to start the e-Bid Submission well in advance so that the submission process passes off smoothly. The Bidder only, will be held responsible if his/ her e-Bids are not submitted in time due to any reasons.

- **Withdrawal and Resubmission of e-Bids**
  - At any point of time, a Bidder can withdraw his/ her e-Bids submitted online before the e-Bids submission end date and time. For withdrawing, the Bidder should first log in using his/ her Login Id and Password and subsequently by his/ her Digital Signature Certificate on the e-tender portal http://etender.up.nic.in. The Bidder should then select the proper option in the Bid Submission menu. The page listing all the Bids submitted by the Bidder will be displayed. Click "View" to see the details of the Bid to be withdrawn. After selecting the "Bid Withdrawal" option, the Bidder has to click "Yes" to the message "Do you want to withdraw this Bid?" displayed in the Bid Information window for the selected Bid. The Bidder also has to enter the Bid Withdrawing reasons and upload the letter giving the reasons for withdrawing before clicking the “Submit" button. The Bidder has to confirm again by pressing "Ok" button before finally withdrawing his/ her selected Bid. Once the Bidder has withdrawn his /her Bid he/she cannot re-submit this Bid again.
  - The Bidder has to request the UPMSCL with a letter, attaching the proof of withdrawal and submission of e-Bids Processing Fee in the office of Managing Director, UPMSCL, to return back the e-Bids Processing Fee as per the procedure.
  - The Bidder can resubmit his/ her e-Bids as and when required till the Bid submission end date and time. The e-Bids submitted earlier will be replaced by the new one. The payment made by the Bidder earlier will be used for revised e-Bids and the new Bid submission summary generated after the successful submission of the revised e-Bids will be considered for

evaluation purposes. For resubmission, the Bidder should first log in using his/ her Login ID and Password and subsequently by his/ her Digital Signature Certificate on the e-procurement portal http://etender.up.nic.in . The Bidder should then select proper option in the Bid Submission menu. The page listing all the Bids submitted by the Bidder will be displayed. Click "View" to see the details of the Bid to be resubmitted. After selecting the "Bid Resubmission" option, click "Encrypt & Upload" to upload the revised e-Bids documents by following the methodology provided below.

- The Bidders can submit their revised Bids as many times as possible by uploading their e-Bids documents within the scheduled date & time for submission of e-Bids.
- No e-Bids can be resubmitted subsequently after the deadline for submission of e-Bids.

- **Receipt and Opening of e-Bids by the Purchaser**
  - Bidders are advised to submit their e-bids in 'Two-Bid' system with Technical and Financial bids separately on e-tender portal.
  - Please note that prices should not be quoted in the Technical Bid. The Prices should be quoted in the Financial Bid only. On receipt on e-tender portal, the technical proposals will be opened first by the Committee members in the office of UPMSCL, Lucknow.
  - UPMSCL will open all e-Bids, in the presence of bidder's authorized representatives who choose to attend at schedule date, time and place mentioned in bid document. After evaluation of technical e-Bids, UPMSCL shall upload the summary of evaluation of technical bid of the bidders as per the Qualification requirements for selection as qualified bidder and further qualified bidder will be considered for opening of their financial e-bids.

Note: The Bidder shall be required to use his own Digital Signature while uploading its Bid. Failure to comply or usage of Digital Signature of other firm shall be liable for rejection of Bid.

ANNEXURE- XI

EDL (Essential Drug List)

S.N.	Drug Code	Drug Name	Formulation	Quoted/ Non Quoted
1	D010020	Aceclofenac : 100 mg (tab)	Tablet	
2	D100021	Acetazolamide : 250 mg (tab)	Tablet	
3	D220007	Acetic acid solution 5% v/v, 100ml Bottle	Oral Solution	
4	D040002	Acyclovir : 400 mg (tab)	Tablet	
5	D040096	Acyclovir oral Suspension 200 mg/5 ml 100 ml Bottle	Suspension	
6	D040086	Acyclovir powder for injection 500mg with diluent, 10 ml water for injection	Injection	
7	D100044	Adenosine Injection 3 mg/ml 2 ml Ampoule	Injection	
8	D130009	Adrenaline Bitartrate injection IP 1/1000 (1mg/1ml), 1 ml Ampoule	Injection	
9	D090001	Albendazole : 200 mg/5 ml (suspension) 10 ml Phial	Suspension	
10	D090002	Albendazole tablet 400mg (chewable fruit flavoured scored)	Tablet	
11	D260001	Allopurinol : 100 mg (tab)	Tablet	
12	D280056	Alprazolam : 0.25 mg (tab)	Tablet	
13	D030014	Ambroxol syrup 15 mg / 5 ml 100 ml bottle	Syrup	
14	D040003	Amikacin sulphate : - 100 mg/2ml : 2ml (inj) Vial	Injection	
15	D040004	Amikacin sulphate : IP - 500 mg/2ml : 2ml (inj) Vial	Injection	
16	D130001	Aminophylline dihydrate : IP - 25 mg/ml : 10ml (inj) Ampoule	Injection	
17	D100045	Amiodarone 100mg tablet	Tablet	
18	D100001	Amiodarone hydrochloride :- 50 mg./ml. : 3ml Ampoule	Injection	
19	D280002	Amitriptyline HCL Tablet 25 mg	Tablet	
20	D040006	Amoxicillin and Potassium clavulanate oral suspension : 200 mg+ 28.5 mg/5 ml (-) 30ml Phial / Bottle	Suspension	
21	D040152	Amoxicillin Sodium : IP - 500 mg : Dry powder (Inj) with water for injection 10 ml	Injection	
22	D040067	Amoxicillin trihydrate dry powder(oral suspension) 125mg /5ml 60ml phial	Suspension	

23	D040051	Amoxicillin trihydrate DT tablet scored 250mg	Tablet	
24	D040010	Amoxicillin trihydrate equivalent to amoxycillin and clavulanate potassium equivalent to clavulanic acid : 500 mg + 125 mg (tab)	Tablet	
25	D040150	Amoxicillin trihydrate with potassium clavunate inj 1.2 gm dry powder vial with water for injection 10 ml	Injection	
26	D040007	Amoxicillin trihydrate with clavulanate : 250 mg+125 mg (tab)	Tablet	
27	D040151	Amoxicilline trihydrate with potassium clavulanate : - 500 mg+100 mg : dry powder (inj) with water for injection 10 ml	Injection	
28	D020006	Antacid tablet, each chewable tablet contains dried aluminium hydroxide IP 240 mg, Magnesium hydroxide IP 100 mg, Light magnesium carbonate IP 60mg, Activated dimethicone IP 25 mg,	Tablet	
29	D020009	Antacid each 5 ml cotntaining magnisium hydroxide 250 mg , aluminium hydroxide 250 mg and simethicone 50 mg, suspension 170 ml Bottle	Suspension	
30	D110013	Artemether (A) + Lumefantrine (B) : tablet 40 mg (a) + 240 mg (b)	Tablet	
31	D110020	Artesunate : IP - 60 mg : dry powder (inj) vial with diluent	Injection	
32	D110014	Artesunate powder for injection 120 mg in 20 ml vial with solvent and diluent (2 ml sodium bicarbonate solvent and 10 ml 0.9% sodium chloride diluent)	Dry Powder Injection	
33	D340001	Ascorbic acid : 500 mg (tab)	Tablet	
34	D010002	Aspirin gastro resistant tab IP 75 mg	Tablet	
35	D010050	Asprin uncoated tablet 325 mg effervescent	Tablet	
36	D100003	Atenolol : 50 mg (tab)	Tablet	
37	D100046	Atorvastatin calcium tablet 40 mg	Tablet	
38	D100004	Atorvastatin calcium : 10 mg (tab)	Tablet	
39	D200002	Atropine sulphate : IP - 0.6 mg/ml : 1 ml (inj) Ampoule	Injection	
40	D270001	Atropine sulphate : 1.0% atropine sulphate, 5 ml FFS eye drop	Eye Drop	

41	D040013	Azithromycin : 500 mg (tab)	Tablet	
42	D040014	Azithromycin suspension 100mg/5ml (-) 30 ml Bottle	Suspension	
43	D230015	B complex : vitamin B1 5 mg thiamine hydrochloride vitamin B2 5mg riboflavin vitamin B6 2 mg pyridoxine hydrochloride vitamin B3 nicotinamide 50 mg vitamin B5 calcium pantothenate 5 mg tablet (tab)	Tablet	
44	D290001	Benzyl Benzoate applicaton : 25% w/v, 100 ml Bottle	Lotion	
45	D160007	Betamethasone :0.5mg (Tab)	Tablet	
46	D160001	Betamethasone sodium phosphate : 4 mg/ml : 1ml (inj) Ampoule	Injection	
47	D160010	Betamethasone Valerate 0.1% w/w Cream 15 gm tube	Cream	
48	D250001	Bisacodyl enteric coated : 5 mg (tab)	Tablet	
49	D250004	Bisacodyl suppository 5 mg,	suppository	
50	D030012	Bromhexine hydrochloride tablet 4 mg	Tablet	
51	D130003	Budesonide : 0.5mg/ml raspule 2 ml	Inhalational Liquid	
52	D130017	Budesonide inhaler 100mcg ; 200 MDI	Inhalational Powder	
53	D300001	Bupivacaine 5mg/ml with dextrose 80 mg/ml Inj 4 ml Ampoule	Injection	
54	D200003	Bupivacaine hydrochloride : IP - 0.5%w/v : 20 ml (inj) vial	Injection	
55	D070016	Cabergoline 0.25 mg tab	Tablet	
56	D340010	Calcium carbonate with vitamin d3 : 1250 mg+250 IU (tab)	Tablet	
57	D230001	Calcium citrate 500 mg elemental calcium tablet	Tablet	
58	D230002	Calcium gluconate : IP - 100 mg : 10 ml (inj) Ampoule	Injection	
59	D340002	Calcium vitamine D3 suspension (each 5ml contains calcium carbonate eq. to elemental calcium 250mg+vitamin d3 -125 IU), 200 ml bottle)	Suspension	
60	D100041	Camylofin Dihydrochloride injection 25 mg, 2 ml Ampoule	Injection	
61	D080009	Carbamazepine : 200 mg CR (tab)	Tablet	
62	D080012	Carbamazepine 100 mg tablet	Tablet	

63	D080001	Carbamazepine susp 100 mg/ 5ml : 100 ml bottle/Phial with measuring cup	Suspension	
64	D310001	Carbimazole : 10 mg tablet	Tablet	
65	D190011	Carboxymethyl cellulose sodium eye drop 1% w/v 10 ml FFS green/amber colour vial	Eye Drop	
66	D040093	Cefazolin Powder for injection 1000 mg with water for injection 10 ml dry powder 10 ml vial	Injection	
67	D040092	Cefazolin Powder for injection 500 mg with water for injection 10 ml dry powder 10 ml vial	Dry Powder Injection	
68	D040015	Cefixime oral suspension IP, 100 mg/5ml ; 30 ml bottle/Phial	Suspension	
69	D040016	Cefixime trihydrate : 200 mg (tab)	Tablet	
70	D040153	Cefotaxime sodium : IP - 1 gm : dry powder (inj) 10 ml vial with water for injection 10 ml	Injection	
71	D040158	Ceftazidime : IP - 1 gm : dry powder (inj) 10 ml vial with water for injection 10 ml	Injection	
72	D040157	Ceftazidime : IP - 250 mg: dry powder (inj) 10 ml vial with water for injection 10 ml	Injection	
73	D040154	Ceftriaxone 1g: dry powder (inj)10 ml vial with water for injection 10 ml	Injection	
74	D040155	Ceftriaxone 500 mg : dry powder (inj) 10 ml vial with water for injection 10 ml	Injection	
75	D040089	Cefuroxime axetil 500 mg (tab) 4 per strip	Tablet	
76	D040025	Cephalexin dry syrup/ dry powder/oral suspension 125mg/5ml (-) 30 ml phial	Suspension	
77	D190001	Chloramphenicol 5% w/v benzocaine 1%w/v : 5% w/v+ 1% w/v, 5 ml, Ear drop	Ear Drop	
78	D210014	Chlorhexidine Solution I.p. 1.5% v/v +Cetrimide solution 3.0% w/v, 500 ml Bottle	Disinfectant fluid	
79	D110003	Chloroquine phosphate : 250 mg (Tab)	Tablet	
80	D030015	Chlorpheniramine maleate : 4 mg (Tab)	Tablet	
81	D100034	Chlorthalidone 12.5mg tablet	Tablet	
82	D340028	Cholecalciferol oral dosage 60000 IU, soft gelatin capsule	Capsule	

83	D340035	Cholecalciferol oral drops 400 IU/ml 15 ml with dropper	Oral Solution	
84	D290030	Ciclopirox olamine cream 1% w/w 20gm tube	Cream	
85	D070009	Cinnarizine : 25 mg (tab)	Tablet	
86	D040047	Ciprofloxacin : 2 mg/ml injection : 100ml FFS bottle	Injection	
87	D040043	Ciprofloxacin hydrochloride : 0.3% w/v 5 ml FFS eye drop	Eye Drop	
88	D040027	Ciprofloxacin hydrochloride : 500 mg (tab)	Tablet	
89	D180035	Clindamycine +Clotrimazole +Tinidazole soft gelatin vaginal suppository 100mg+100mg+ 100mg,	Tablet	
90	D280022	Clobazam : 5mg tablet	Tablet	
91	D290019	Clobetasol propionate Cream 0.05% w/w ; 15 gm Tube	Cream	
92	D280080	Clomipramine 25mg tablet		
93	D280003	Clonazepam : 0.5 mg (tab)	Tablet	
94	D100005	Clopidogrel : 75 mg (tab)	Tablet	
95	D290003	Clotrimazole : 2% w/w (Cream) ; 15 gm tube	Cream	
96	D180002	Clotrimazole vaginal : 200 mg (with applicator) (tab)	Pessaries	
97	D190020	Clotrimazole+lignocaine HCl Ear drop 1%+2%w/v 10ml FFS vial	Ear Drop	
98	D160002	Dexamethasone : 0.5mg (tab)	Tablet	
99	D160003	Dexamethasone sodium phosphate : IP - 4 mg/ml : 2ml (inj) vial	Injection	
100	D240002	Dextrose : IP - 10% w/v : 500 ml (inj) FFS Bottle	Injection	
101	D240003	Dextrose : IP - 5% w/v : 500 ml (inj) FFS Bottle	Injection	
102	D240001	Dextrose injection - 25% w/v : 100 ml (inj) FFS Bottle	Injection	
103	D240013	Dextrose monohydrate : IP 75 gm powder	Oral Powder	
104	D240004	Dextrose with sodium chloride : IP - 5% w/v +0.9%w/v : 500ml (inj) FFS Bottle	Injection	
105	D280004	Diazepam : IP - 5 mg/ml : 2ml (inj) Ampoule	Injection	
106	D010003	Diclofenac gel (Diclofenac sodium 1% w/w) 30gm tube	Gel	

107	D010016	Diclofenac sodium 50mg tab (Equivalent to Diclofenac Sodium gastro-resistant 50 mg tab).	Tablet	
108	D010004	Diclofenac sodium inj 75mg/ml, 1ml ampoule	Injection	
109	D010005	Diclofenac sodium SR tablet 100 mg	Tablet	
110	D120002	Dicyclomine hydrochloride - 10 mg/ml : 2ml (inj) Ampoule	Injection	
111	D120003	Dicyclomine hydrochloride : 10 mg (tab)	Tablet	
112	D120005	Dicylomine Hcl with activated Dimethicone 10 mg+40 mg per ml, 10ml drop Suspension	Suspension	
113	D120004	Dicylomine hcl with simethicone : 10 mg+40 mg/5ml Suspension 30 ml bottle with measuring cap	Suspension	
114	D090003	Diethylcarbamazine citrate : 100 mg (tab)	Tablet	
115	D100006	Digoxin 0.25 mg tablet	Tablet	
116	D100047	Diltiazem hydrochloride injection 5 mg/ml 5ml vial	Injection	
117	D100007	Diltiazem hydrochloride : 30 mg (tab)	Tablet	
118	D180025	Dinogest Tablet 2 mg	Tablet	
119	D350002	Disodium hydrogen citrate liquid/syrup : 1.4 gm/5 ml bottle with measuring cup 100 ml Bottle	Syrup	
120	D100008	Dobutamine hydrochloride : USP - 50 mg/ml : 5ml (inj) Ampoule	Injection	
121	D070001	Domperidone : 10 mg (tab)	Tablet	
122	D070002	Domperidone suspension 1 mg/ml 30ml phial	Suspension	
123	D080030	Donepezil 5 mg tablet	Tablet	
124	D100009	Dopamine hydrochloride :- 40 mg/ml : 5ml (inj) Ampoule	Injection	
125	D040029	Doxycycline hydrochloride : equivalent of 100mg Doxycycline (caps)	Capsule	
126	D040090	Doxycycline oral suspension 50 mg/5 ml (60ml bottle)	Suspension	
127	D070010	Doxylamine succinate with pyridoxine HCL : 10 mg+10 mg (tab)	Tablet	
128	D010041	Drotaverine HCL suspension 20mg/5ml 60ml Bottle	Suspension	

129	D280065	Duloxeitine hydrochloride : 20 mg (tab)	Tablet	
130	D070017	Ebastine IP 10 mg tablet	Tablet	
131	D290012	Enema glycerin 15% w/v and sodium chloride 15% w/v 100 ml Packet	Enema	
132	D280026	Escitalopram : 10 mg (tab)	Tablet	
133	D150005	Ethamsylate : 500 mg (tab)	Tablet	
134	D050006	Ethamsylate injection - 125 mg/ml : 2 ml Ampoule	Injection	
135	D210013	Ethyl alcohol (Denatured) Solution 70% v/v, pack size 500ml Bottle	Disinfectent Fluid	
136	D260003	Febuxostat 40 mg tab	Tablet	
137	D010044	Fentanyl citrate injection 50 mcg/ml (2ml) vial	Injection	
138	D230049	Ferric Carboxy Maltose injection 50 mg/ml, 20 ml Vial	Injection	
139	D230022	Ferrous ascorbate 100 mg + Folic acid 1.5 mg tablet	Tablet	
140	D230004	Ferrous Sulphate : 200mg equivalent to 60 mg Ferrous ion (Tab)	Tablet	
141	D040030	Fluconazole : 150 mg (Tab)	Tablet	
142	D280005	Fluoxetine Capsule 20 mg IP	Capsule	
143	D280006	Fluphenazine Deconate inj USP 25 mg/ml, 5ml vial	Injection	
144	D190015	Flurbiprofen sodium : 0.03% w/v 5 ml FFS, eye drop	Eye Drop	
145	D340003	Folic acid tablet : 5 mg	Tablet	
146	D130030	Formetrol fumarate 6mcg+Budesonide 400mcg powder for inhalation pack of 30 capsule(with free of cost compatible inhalation device with 60 capsule or 2 pack of 30 capsule)	Inhalational Powder	
147	D290004	Framycetin Sulphate : 1% w/w 30 gm Tube	Ointment	
148	D100023	Furosemide : IP - 10 mg/ml : 2ml (inj) Ampoule	Injection	
149	D100022	Furosemide: 40 mg (Tab)	Tablet	
150	D080029	Gabapentine 300 mg Tablet	Tablet	
151	D270012	Gentamicin Eye Drop 0.3%w/v, 10 ml FFS eye drop	Eye Drop	
152	D040032	Gentamicin sulphate : IP - 40 mg/ml : 2 ml vial	Injection	
153	D060001	Glibenclamide : 5 mg (Tab)	Tablet	
154	D060002	Gliclazide :40 mg (Tab)	Tablet	

155	D060003	Glimepride : 1 mg (Tab)	Tablet	
156	D060004	Glimepride : 2 mg (Tab)	Tablet	
157	D060005	Glipizide : 5 mg (Tab)	Tablet	
158	D290020	Glycerin/glycerol topical IP 98% 100 ml Bottle (Liquid)	Topical Solution	
159	D100012	Glyceryl trinitrate 5mg/ml 5 ml Ampoule	Injection	
160	D100039	Glyceryl trinitrate sublingual tablet 0.5 mg 30 tablet per container	Tablet	
161	D200005	Glycopyrrolate : IP - 0.2 mg/ml : 1 ml (inj) Ampoule	Injection	
162	D280008	Haloperidol lactate : IP - 5mg/ml : 1ml (inj) Ampoule	Injection	
163	D280007	Haloperidol tab 5 mg IP	Tablet	
164	D280046	Haloperidol tab 1.5 mg	Tablet	
165	D270011	Homatropine hydrobromide drops 2% w/v , 5 ml FFS eye drop	Eye Drop	
166	D100013	Hydrochlorthiazide : 12.5mg (Tab)	Tablet	
167	D160005	Hydrocortisone sodium succiinate : IP - 100 mg : dry powder (inj) vial	Injection	
168	D220003	Hydrogen Peroxide Solution I.P. : 6% w/v 400 ml Bottle	Disinfectant	
169	D030013	Hydroxyzine hcl : 10 mg/5 ml (syr) 30 ml Phial	Syrup	
170	D050009	Hydroxy ethyl starch 6% injection IV Infusion 500 ml FFS bottle	Injection	
171	D260004	Hydroxychloroquine 200 mg Tablet	Tablet	
172	D180019	Hydroxyprogesterone caproate Inj 250mg/ml ; 2ml Ampoule	Injection	
173	D010040	Hyoscine butyl bromide injection 20 mg/ ml, 1ml Ampoule	Injection	
174	D010007	Ibuprofen Suspension: 100 mg/5 ml , 60 ml bottle with measuring cup	Suspension	
175	D010006	Ibuprofen Tab 200 mg	Tablet	
176	D260002	Indomethacin : 25 mg (caps)	Capsule	
177	D130004	Ipratropium bromide MDI 20mcg/puff, 200 doses aerosol inhaler	Inhalational Powder	
178	D130005	Ipratropium Bromide respiratory solution 250 mcg/ml, 15ml bottle	Inhalational Liquid	
179	D230005	Iron and Folic acid containing dried ferrous sulphate IP : equivalent to ferrous iron 60 mg & folic acid 0.5 mg IFA wifs large blue coloured indigo carmine Tablet	Tablet	

180	D230007	Iron and folic acid IFA (wifs-junior) containing dried ferrous sulphate eq to ferrous iron 45 mg and folic acid 0.4mg : 45 mg+0.4 mg pink IFA wifs junior (tab)	Tablet	
181	D230006	Iron and Folic Acid IFA Large Tablet Containing 60 mg Elemental Iron + 500 mcg Folic Acid, Sugar Coated, Red Color	Tablet	
182	D230023	Iron Dextran injection 50mg/ml, 2ml ampoule	Injection	
183	D230055	Iron sucrose containing ferric hydroxide as complex with sucrose eq to elemental iron 20 mg/ml : - 20 mg/ml : 2.5ml (inj) Ampoule	Injection	
184	D230056	Iron sucrose containing ferric hydroxide as complex with sucrose eq to elemental iron 20mg/ml : 20 mg/ml : 5ml (inj) Ampoule	Injection	
185	D230010	Iron with folic acid : 20 mg+100 mcg/ml 50 ml Bottle with Auto dispensor (syr)	Syrup	
186	D250003	Isabgol Husk 100 gm per Bottle	Oral Powder	
187	D200006	Isoflurane IP 100ml bottle	Inhalational Liquid	
188	D100014	Isosorbide Dinitrate : 5 mg (Tab)	Tablet	
189	D180020	Isoxsuprine Hydrochloride injection 5mg/ml, 2 ml Ampoule	Injection	
190	D090005	Ivermectin : 12 mg Tablet	Tablet	
191	D040159	Kanamycin Powder for Injection 500mg (10 ml vial with 10 ml water for injection)	Injection	
192	D200008	Ketamine hydrochloride : IP - 10 mg/ml : 10ml (inj) vial	Injection	
193	D200007	Ketamine hydrochloride 50 mg/ml. : 10ml (inj) vial	Injection	
194	D180008	Labetalol HCL : 100 mg Tablet	Tablet	
195	D180009	Labetalol HCL :5 mg/ml : 20 ml vial	Injection	
196	D250020	Lactulose syrup 10 gm/15ml, 100 ml Bottle	Syrup	
197	D280049	Levodopa (A)+ Carbidopa(B) 200mg(A)+ 50mg(B) Tablet	Tablet	
198	D280047	Levodopa(A)+ Carbidopa(B) 250 mg (A)+ 25 mg (B) tablet	Tablet	
199	D280048	Levadopa(A)+ Carbidopa(B) Modified Release tablet 100mg(A)+ 25mg(B)	Tablet	
200	D280057	Levetiracetam 500 mg tablet	Tablet	
201	D280050	Levetiracetam injection 100mg/ml 5ml vial	Injection	
202	D030030	Levocetirizine syrup 2.5mg/5ml : 60 ml bottle	Syrup	
203	D030002	Levocetirizine tablet 5 mg	Tablet	
204	D040033	Levofloxacin : 500 mg (tab)	Tablet	

205	D180022	Levonorgestrel tab 1.5 mg	Tablet	
206	D130012	Levosalbutamol : 1 mg/5 ml (syrup) 30 ml Bottle	Syrup	
207	D310003	Levothyroxine 25 mcg Tab, 100 tablet per Bottle	Tablet	
208	D310004	Levothyroxine 50 mcg (0.05mg) Tab, 100 tablet per Bottle	Tablet	
209	D200009	Lignocaine gel : 2% w/v 30 gm tube	Gel	
210	D200010	Lignocaine HCL : 2%w/w : 30ml (inj) vial	Injection	
211	D200030	Lignocaine HCL :4%w/v topical solution, 30 ml Bottle	Topical Solution	
212	D200011	Lignocaine HCL with adrenaline injection (lignocaine HCL 20mg/ml adrenaline bitartate eq. to adrenaline 5mcg/ml) : 30ml vial	Injection	
213	D280011	Lithium carbonate 300 mg tablet	Tablet	
214	D280051	Lorazepam Injection 2 mg/mL, 1ml vial	Injection	
215	D280037	Lorazepam Tablet 2 mg	Tablet	
216	D100029	Losartan potassium : 50 mg (tab)	Tablet	
217	D220008	Lugol's iodine solution 5% w/v 50 ml Botlle	Oral Solution	
218	D180011	Magnesium sulphate injection 50% w/v in 2 ml ampoule	Injection	
219	D240012	Mannitol : IP - 20% w/v : 100ml (inj) FFS Bottle	Injection	
220	D180012	Medroxyprogestrone acetate 10mg tablet	Tablet	
221	D010039	Mefenamic acid oral suspension 100 mg/5 ml, 60ml bottle with measuring cup	Suspension	
222	D010027	Mefenamic acid tablet 250 mg	Tablet	
223	D100026	Mephentramine injection 30 mg/ml, 10 ml vial	Injection	
224	D040166	Meropenem 1 gm inj (20 ml vial with 10 ml water for injection) IP	Injection	
225	D040094	Meropenem 250 mg inj dry powder 10 ml vial with 10 ml water for injection combi pack	Injection	
226	D060009	Metformin hydrochloride : 500 mg (tab)	Tablet	
227	D140014	Methotrexate tablet 5 mg	Tablet	
228	D340036	Methylcobalamine -1500 mcg	Tablet	
229	D230011	Methylcobalamine -500 mcg/ml : 3ml (inj) Ampoule	Injection	
230	D220010	Methylergometrine maleate 0.2 mg injection 1 ml Ampoule	Injection	
231	D160016	Methylprednisolone Acetate Injection 40 mg/ml, 1 ml vial	Injection	
232	D290021	Methylrosanilinium chloride (Gentian Violet) 1% w/v , 50ml Bottle (liquid)	Disinfectant Fluid	

233	D070003	Metoclopramide hydrochloride injection 5 mg/ml in 2ml : ampoule	Injection	
234	D070014	Metoclopramide syrup 5 mg/5 ml 30 ml Phial	Syrup	
235	D070018	Metoclopramide Tablet 10 mg IP	Tablet	
236	D100017	Metoprolol : 50mg (tab)	Tablet	
237	D100040	Metoprolol tablet 25 mg	Tablet	
238	D170002	Metronidazole : 200 mg tablet	Tablet	
239	D040040	Metronidazole : 400 mg tablet	Tablet	
240	D040042	Metronidazole : IP - 5 mg/ml : 100 ml (inj) FFS Bottle	Injection	
241	D040041	Metronidazole benzoate suspension 40mg/ml, 60 ml Phial	Suspension	
242	D180024	Micronised Progesterone 200 mg soft gelatine capsule	Capsule	
243	D200013	Midazolam HCL 1 mg/ml in 10ml (inj) vial	Injection	
244	D280055	Midazolam nasal spray 5mg/ml, 5ml spray	Nasal Spray	
245	D180013	Mifepristone tablet 200 mg	Tablet	
246	D180014	Misoprostol : 200 mcg (tab)	Tablet	
247	D030003	Montelukast sodium : 10 mg (tab)	Tablet	
248	D270010	Moxifloxacin eye drop 0.5 % w/v 5ml FFS vial	Eye Drop	
249	D240005	Multiple electrolytes and dextrose type-1 (Isolyte P) : - Sodium acetate trihydrate 0.32gm Potassium chloride 0.13gm Dipotassium hydrogen phosphate heptahydrate 0.026gm magnisium chloride hexahydrate 0.031gm Dextrose 5.0gm Water for injection to 100ml pH 5.0 : 500ml (Inj) FFS Bottle	Injection	
250	D240006	Multiple electrolytes and dextrose type-3(Isolyte M) : - Sodium acetate trihydrate 0.28gm Sodium chloride 0.091gm Potassium chloride 0.15gm Dipotassium hydrogen phosphate heptahydrate 0.13gm Dextrose 5.0gm Water for injection to 100ml pH5 : 500ml FFS Bottle	Injection	
251	D340005	Multivitamin drops each ml contains vit-a-3000iu, vit d3 - 300iu, vit- b1 -1mg, riboflavine phosphate sodium- 2mg, d-pentenol-2.5mg, niacinamide-10mg, pyridoxime hcl- 1mg, cynocobalamine 1 mcg, lysine hcl 10 mg, 15	Oral Drop	
252	D340034	Multivitamin Tablet:- Vitamin A 400mcg, Thiamine 0.7mg, Riboflavin 0.8mg, Vitamin B6 0.8mg, Vitamin B12 1mcg, Folic Acid 75mcg, Nilacin 9mg, Pantothenic Acid 3mg, Vitamin C 40mg, Vitamin D 10mg, 50 tablets per Bottle ml vial with dropper	Tablet	
253	D290015	Mupirocin ointment 2% w/w 5 gm tube	Ointment	
254	D010043	Naloxone injection 0.4 mg/ml, 1 ml Ampoule	Injection	
255	D200014	Neostigmine methyl sulphate : IP - 0.5 mg/ml : 5ml (inj) Ampoule	Injection	

256	D280024	Nicotine pastille/gum 4mg chewable gum	Chewing Gum	
257	D100018	Nifedipine : 10 mg capsule	Capsule	
258	D130018	Nikethamide injection 250 mg/ml 2 ml ampoule	Injection	
259	D040035	Nitrofurantoin :100 mg tablet	Tablet	
260	D200015	Noradrenaline tartrate : 2 mg/ ml : 2ml (inj) Ampoule	Injection	
261	D180015	Norethisterone : 5 mg (tab)	Tablet	
262	D040062	Norfloxacin : 100 mg/5 ml (suspension) 60 ml Phial	Suspension	
263	D040036	Norfloxacin : 400 mg (tab)	Tablet	
264	D040037	Ofloxacin : 200 mg (tab)	Tablet	
265	D280028	Olanzapine : 10 mg tablet	Tablet	
266	D280059	Olanzapine injection: 10 mg /vial: dry powder in 5 ml with 2 ml water for injection	Dry Powder Injection	
267	D020001	Omeprazole IP : 20 mg. (caps) (Equivalent to omeprazole 20 mg gastro resistant capsule)	Capsule	
268	D070006	Ondansetron IP inj 2 mg/ml in 2 ml ampoule	Injection	
269	D070004	Ondansetron HCL : 2 mg base/5 ml (30 ml bottle/Phial with measuring cap) (syr)	Syrup	
270	D070005	Ondansetron HCL : 4 mg (tab)	Tablet	
271	D170001	Oral rehydration salts citrate (W.H.O. formula) : ORS 20.5gm.each sachet contains sodium chloride ip 2.6g potassium chloride IP 1.5g sodium citrate IP 2.9g anhydrous dextorse ip 13.5g for making 1 ltr	Oral Powder	
272	D220005	Oseltamivir oral suspension IP 12 mg/ml 75 ml Phial	Suspension	
273	D040038	Oseltamivir phosphate : 75mg (caps)	Capsule	
274	D020002	Pantaprazole injection 40 mg/vial with dilutant (0.9% w/v sodium chloride 10 ml) dry powder	Injection	
275	D020010	Pantoprazole IP 40 mg (tab) (Equivalent to 40 mg gasto resistant pantoprazole tablet)	Tablet	
276	D010009	Paracetamol drop : 100mg/ml (15 ml pack with dropper)	Oral Solution	
277	D010008	Paracetamol 500 mg (tab)	Tablet	
278	D010051	Paracetamol infusion injection 10 mg/ml 100ml FFS bottle	Injection	
279	D010010	Paracetamol injection: IP – 150 mg/ml : 2ml Ampoule	Injection	
280	D010015	Paracetamol suspension 250 mg/5ml 60ml bottle with measuring cup	Suspension	
281	D010014	Paracetamol syrup 125 mg/ 5ml with measuring cup 60 ml phial	Syrup	

282	D280052	Paroxetine HCL 25 mg prolonged release tablet IP	Tablet	
283	D010011	Pentazocine lactate : IP - 30 mg/ml : 1ml (inj) Ampoule	Injection	
284	D290007	Permethrin : 5% w/w (Cream) 60 gm Tube	Cream	
285	D010042	Pethidine injection 50 mg /ml 1 ml Ampoule	Injection	
286	D030004	Pheniramine maleate injection 22.75 mg/ml in 2ml ampoule	Injection	
287	D080031	Phenobarbitone sodium injection 200 mg/ml (1ml) Ampoule	Injection	
288	D080004	Phenobarbitone syrup 20 mg/5 ml, 60 ml bottle/Phial with measuring cup	Syrup	
289	D080003	Phenobarbitone tablet 60 mg	Tablet	
290	D080005	Phenytoin 100 mg tablet	Tablet	
291	D080006	Phenytoin sodium injection 50 mg./ml. in 2 ml ampoule	Injection	
292	D230012	Phytomenadione vit.K1 : IP - 1mg/ml : 1ml (inj) Ampoule	Injection	
293	D270015	Pilocarpine nitrate : 1% w/v, 5 ml FFS eye drop	Eye Drop	
294	D040156	Piperacillin with Tazobactam sodium - 4gm + 500mg : dry powder (inj) 20 ml vial with water for injection 20 ml	Injection	
295	D240016	Potassium Chloride injection 150 mg/ml 10 ml Ampoule	Injection	
296	D290014	Povidione iodine surgical scrub solution 7.5% w/v, 50 ml Bottle	Disinfectant Fluid	
297	D290008	Povidone iodine Ointment: 5% w/w 15 gm tube	Ointment	
298	D290016	Povidone iodine Solution 10% w/v, 100 ml bottle	Topical Solution	
299	D320003	Pralidoxime chloride (2-PAM) inj 500mg/ 20 ml ampoule	Injection	
300	D160030	Prednisolone sodium phosphate : 1.0% w/v, 5ml FFS eye drop	Eye Drop	
301	D160006	Prednisolone : 10 mg (tab)	Tablet	
302	D160011	Prednisolone : 5 mg (tab)	Tablet	
303	D160014	Prednisolone Injection 10mg/ml mL, 10 ml vial	Injection	
304	D160015	Prednisolone Sodium phosphate syrup 5 mg/5 mL 60 ml Phial	Syrup	
305	D110006	Primaquine tablet 7.5 mg	Tablet	
306	D070030	Promethazine hydrochloride : 25 mg tablet	Tablet	
307	D070007	Promethazine hydrochloride : 25 mg/ml : 2ml (inj) Ampoule	Injection	

308	D070008	Promethazine hydrochloride : 5 mg/5 ml (syr) 60 ml Phial	Syrup	
309	D280029	Propranolol hydrochloride : 20mg (tab)	Tablet	
310	D050007	Protamine Sulphate injection 10 mg/ml 5 ml Ampoule	Injection	
311	D340026	Pyridoxine tablet 50 mg	Tablet	
312	D280027	Quetiapine fumarate : 100 mg (tab)	Tablet	
313	D110012	Quinine injection 300mg/ml	Injection	
314	D110011	Quinine tablet 300 mg	Tablet	
315	D100030	Ramipril : 5 mg (tab)	Tablet	
316	D020004	Ranitidine hydrochloride : IP - 25 mg/ ml : 2ml (inj) Ampoule	Injection	
317	D020003	Ranitidine hydrochloride : 150 mg (tab)	Tablet	
318	D340037	Riboflavin 10 mg tablet	Tablet	
319	D240008	Ringer lactate : IP - 0.24%w/v lactic acid (eq.0.32% w/v sod.lac.) with 0.6%w/v sod.cl., 0.04% w/v pot.cl. & 0.027% w/v cal cl : 500 ml (inj) FFS Bottle	Injection	
320	D280053	Risperidone : 1 mg. (tab)	Tablet	
321	D280015	Risperidone : 2 mg. (tab)	Tablet	
322	D100031	S Amlodipine besylate : 5mg (tab)	Tablet	
323	D130022	Salbutamal inhalation 2.5mg/2.5ml, 2.5ml respule	Inhalational Liquid	
324	D130006	Salbutamol 5 mg/ml respiratory solution 15 ml bottle	Inhalational Liquid	
325	D130014	Salbutamol aerosol 200mtd, 100mcg/metered dose inhaler	Inhalational Powder	
326	D130007	Salbutamol sulphate : 4 mg (tab)	Tablet	
327	D290018	Salicylic acid ointment 6% w/w, 20 gm tube	Ointment	
328	D130011	Salmeterol 25 mcg + fluticasone 250 mcg 120 MDI 25 mcg + 250 mcg inhaler	Inhalational Powder	
329	D170005	Senna 100 tablet per Bottle	Tablet	
330	D280054	Sertaline hydrochloride 50 mg tablet	Tablet	
331	D290010	Silver sulphadiazine Cream : 1% w/w 250 gm jar	Cream	
332	D290017	Silver sulphadiazine Cream 1% w/w 10 gm tube	Cream	

333	D240009	Sodium bicarbonate : - 7.5% w/v : 10 ml (inj) Ampoule	Injection	
334	D240010	Sodium chloride : IP - 0.9% w/v : 500 ml (inj) FFS Bottle	Injection	
335	D240014	Sodium chloride injection 0.9 % w/v in 100 ml FFS bottle	Injection	
336	D080040	Sodium valporate / valporic acid oral syrup 200mg/5ml, 200 ml bottle/Phial with measuring cup	Syrup	
337	D080010	Sodium valproate : 500 mg CR (tab) (Valproic Acid equivalent to 500 mg CR)	Tablet	
338	D080013	Sodium valproate 200 mg (tab) (Valproic Acid equivalent to 200 mg CR tablet)	Tablet	
339	D100024	Spironolactone : 25 mg (tab)	Tablet	
340	D010053	Streptococcus faecalis+clostridium butyricum+bacillus mesentericus+lactic acid bacillus capsule 30 millions spores 2 millions spores 1 millions spores 50 millions sproes, 10 capsule per strip	Capsule	
341	D350003	Tamsulosin HCL prolonged release capsules 400 mcg	Capsule	
342	D100019	Telmisartan : 40 mg (tab)	Tablet	
343	D040091	Terbinafine 250 mg tablet	Tablet	
344	D130015	Theophylline with etophylline : 69 mg+231 mg (tab)	Tablet	
345	D130008	Theophylline with etophylline : IP – 25.3 mg +84.7 mg/ml : 2ml (inj) Ampoule	Injection	
346	D340033	Thiamine injection 100 mg/ml, 2ml Vial	Injection	
347	D340032	Thiamine tablet 100 mg	Tablet	
348	D270016	Timolol Maleate drops 0.5 % w/v , 5 ml FFS eye drop	Eye Drop	
349	D170004	Tinidazole 500 mg tablet	Tablet	
350	D010013	Tramadol hydrochloride : IP – 50 mg/ ml : 2ml (inj) Ampoule	Injection	
351	D010052	Tramadol hydrochloride :50 mg Capsule	Capsule	
352	D050005	Tranaxamic acid injection 500 mg/5ml 5 ml Ampoule	Injection	
353	D150002	Tranaxamic acid injection 500 mg/5ml 5 ml Ampoule	Injection	
354	D280016	Trihexyphenidyl hydrochloride : 2 mg (tab)	Tablet	
355	D040066	Trimethoprim with sulphamethoxozole : 160 mg+800 mg (tab)	Tablet	
356	D040039	Trimethoprim with sulphamethoxozole : 40 mg +200 mg /5 ml 50 ml phial (-)	Suspension	

		Suspension		
357	D160031	Tropicamide : 1% w/v, 5ml FFS eye drop	Eye Drop	
358	D010038	Trypsin Chymotrypsin (100000AU) tablet	Tablet	
359	D200021	Vecuronium bromide - 10 mg : dry powder (inj) vial	Injection	
360	D100020	Verapamil HCL : 40 mg (tab)	Tablet	
361	D060013	Vildagliptin : 50 mg (tab)	Tablet	
362	D340006	Vitamin a palmipate arachis oil base liquid 100000 IU/ml, 100 ml bottle with feeding spoon (to be packed in mono carton)	Oral Solution	
363	D340007	Vitamin a softgelatin Capsule: 25000 IU (-) capsule	Capsule	
364	D050008	Warfarin 2 mg tablet	Tablet	
365	D240011	Water for injection in 10 ml ampoule	Injection	
366	D190002	Wax dissolving ear drops : Paradichlorobenzene, Benzocaine, Chlorobutanol, Turpentine oil 2% +2.7% +5% +15% ; 15 ml bottle with dropper	Ear Drop	
367	D030031	Xylometazoline : 0.05% w/v 10 ml nasal drop	Nasal Drop	
368	D230013	Zinc sulphate dispersible DT tablet: eq. to elemental zinc 20mg	Tablet	
369	D280017	Zolpidem tartarate : 5 mg (tab)	Tablet	

ANNEXURE- XII

Non - EDL (Essential Drug List)

S.N.	Drug Code	Drug Name	Formulations	Quoted / Non Quoted
1	D180070	1 tab Mifepristone-200mg+ 4 tabs, Misoprostol-200mcg in a kit (MMA combi pack)	Tablet	
2	D360002	2 FDC-P Fixed Dose Combination - Ped.- Isoniazid 50mg, Rifampicine 75 mg dispersible tab	Tablet	
3	D360004	3 FDC CP -Adult- Fixed Dose Combination - Ped. - Isoniazid 75 mg, Rifampicine 150mg, Ethambutol 275mg	Tablet	
4	D360001	3 FDC-P Fixed Dose Combination-PED.- Isoniazid 50mg, Rifampicine 75mg, Pyrazinamid 150mg Dispersible Tab	Tablet	
5	D360003	4 FDC-Adult-Fixed Dose Combination- Isoniazid 75mg, Rifampicine 150mg, Pyrazinamide 400mg, Ethambutol 275mg	Tablet	
6	D010034	Aceclofenac 100 mg + Paracetamol 325 mg Tablet	Tablet	
7	cyp	Alpha cypermethrin 5% WP, 25 kg pack	Insecticidal Powder	
8	D280001	Alprazolam : 0.5 mg (Tab)	Tablet	
9	D040050A	Amoxycillin 500 mg (Tab)	Tablet	
10	D040050B	Amoxycillin 500 mg (Cap)	Capsule	
11	D040009	AmoxycillinTrihydrate Dispersible 125mg Tablet	Tablet	
12	D100111	Apixaban 2.5 mg Tablet	Tablet	
13	D010080	Asprin chewable tablet IP 300 mg	Tablet	
14	D100032	Atorvastatin Calcium : 20 mg (Tab)	Tablet	
15	D100101	Atorvastatin 80 mg (Tab)	Tablet	
16	G03004a	Bacillus Thuringiensisisraelensis, varisraelensis, 5% AS	Insecticidal Liquid	
17	G03004	Bacillus Thuringiensisisraelensis, varisraelensis, strain 164 serotype-H14 WP (Wettable Powder)	Insecticidal Powder	
18	D040100	Bedaquiline (BDQ) ; 100 mg	Tablet	
19	D020051	Betahistine 16 mg (Tab)	Tablet	
20	D020050	Betahistine 8 mg (Tab)	Tablet	
21	D030006	Bromhexine Hydrochloride : 8mg (Tab)	Tablet	

22	D130100	Budesonide 200 mcg, 200 MTD Inhaler (Spacer to be provided for each 50)	Inhalational powder	
23	D130101	Budesonide powder for Inhalation 200 mcg, pack of 30 capsules, one compatible inhalation device to be provided with 300 capsules.	Inhalational powder	
24	D130102	Budesonide powder for Inhalation 400 mcg, pack of 30 capsules, one compatible inhalation device to be provided with 300 capsules.	Inhalational powder	
25	D010026	Buprenorphine 2 mg Sublingual Tablet	Tablet	
26	D290025	Calamine Lotion IP 100ml	Lotion	
27	D340070	Calcium with Vitamine D Tablets USP/ Calcium and Colealciferol Tablets BP/ Calcium and Vitamin D3 Tablets IP (Elemental Calcium 500mg, Vitamin D3-250 IU) (Non-Chewable)	Tablet	
28	D040046	Ceftazidime : IP - 1 gm : dry powder (Inj), 20 ml Vial	Injection	
29	D040018	Ceftazidime: IP - 250 mg : dry powder (Inj), 5 ml Vial	Injection	
30	D040023	Cephalexin : 250 mg (Caps)	Capsule	
31	D030007	Cetirizine Dihydrochloride : 10 mg (Tab)	Tablet	
32	D340011	Cholecalciferol : 60000IU/ 1gm Sachet	Oral Powder	
33	D040087	Clotrimazole 1% w/w 30 gm Powder bottle	Powder	
34	D040080	Cycloserine 250 mg (Cap)	Capsule	
35	D040078	Daclatasvir 60 mg Tablets	Tablet	
36	D060080	Dapagliflozin 10 mg Tablet	Tablet	
37	D160023	Dexamethasone 4 mg (Tab)	Tablet	
38	D280045	Diazepam : 5 mg (Tab)	Tablet	
39	D040071	Dolutegravir IP 50 mg	Tablet	
40	D040082	Entecavir : 0.5 mg (Tab)	Tablet	
41	M-100	Entecavir : 1 mg (Tab)	Tablet	
42	D360006	Ethambutol : 100 mg Dispersible Tablet	Tablet	
43	D360007	Ethambutol : 200 mg (Tab)	Tablet	
44	D360008	Ethambutol : 400 mg (Tab)	Tablet	
45	D360009	Ethambutol : 800 mg (Tab)	Tablet	
46	D360010	Ethionamide 125 mg (Tab)	Tablet	
47	D360011	Ethionamide 250 mg (Tab)	Tablet	
48	D280043	Fentanyl transdermal patch 25 mcg	Transdermal Patch	
49	D100035	Flunarizine 10mg Tablet	Tablet	

50	D280033	Fluoxetine 40 Mg Capsule	Capsule	
51	D230020	Folic Acid (B9) : 400 mcg (Tab)	Tablet	
52	D130103	Formeterol 20 mcg and Budesonide 0.5mg Respitory Solution/ Suspension, 2ml	Inhalational Liquid	
53	D130104	Formoterol Fumerate & Budesonide Powder For Inhalation IP 12 mcg + 400 mcg, 30 capsule, one compatible inhalation device to be provided with 300 capsules.	Inhalational Powder	
54	D130025	Formoterol Fumerate & Budesonide Powder For Inhalation IP 6 mcg + 200 mcg,	Inhalational Powder	
55	D080100	Fosfomycin trometamol powder 3 gm, Sachet	Oral Powder	
56	D080027	Gabapentine 100mg Tablet	Tablet	
57	D040074	Gentamicin Sulphate : IP - 10 mg/ml : 2 ml (Inj)	Injection	
58	D100100	Glycerine 80% w/w Sodium Stearate 15% w/w Suppository	Suppository	
59	D280009	Imipramine 25 mg Tablet	Tablet	
60	D130021	Indacaterol 110 mcg + Glycopyrronium 50 mcg. Capsule (Powder for Inhalation)	Inhalational Powder	
61	D360013	Isoniazid : 300 mg (Tab)	Tablet	
62	D010037	Ketorolac Tromethamine Dispersible Tablet 10 mg (each Uncoated Dispersible tablet contains Ketorolac Tromethamine 10 mg	Tablet	
63	D180010	Labetalol HCL : - 5 mg/ml : 4 ml (Inj)	Injection	
64	D080017	Levetiracetam 250 mg (Tab)	Tablet	
65	D040081	Levofloxacin IP : 250 mg (Tab)	Tablet	
66	D130026	Levosalbutamol Respule 1.25 mg/2.5 ml, 2.5ml respules	Inhalational Liquid	
67	D250012	Liquid Paraffin 1.25 ml + Milk of Magnesia 3.75 ml + Sodium picosulfate 3.33 mg in each 5 ml Syrup, 200 ml bottle	Syrup	
68	D040083	Linezolid : 600 mg (Tab)	Tablet	
69	D010018	Malathion TC 95%	Insecticidal	
70	D010031	Mefenamic Acid : 500 mg (Caps)	Capsule	
71	D080101	Melatonin 3 mg (Tab)	Tablet	
72	D080102	Melatonin 5 mg (Tab)	Tablet	

73	D010036	Meloxicam 15 mg (Tab)	Tablet	
74	D130023	Memantine (Tab) 5 mg	Tablet	
75	D060081	Metformin SR 1000 mg (Tab)	Tablet	
76	D100016	Methyldopa : 250 mg Tablet	Tablet	
77	D280036	Mirtazapine (Tab) 7.5 mg	Tablet	
78	D030050	Montelukast (10 mg) + Levocetrizine (5 mg) tab	Tablet	
79	D200022	Morphine : 10mg (Tab)	Tablet	
80	D040085	Moxifloxacin : 400mg (Tab)	Tablet	
81	D130029	N-Acetyl Cysteine 600 mg (Tab)	Tablet	
82	D010032	Naproxen (Tab) 250mg	Tablet	
83	D010033	Naproxen (Tab) 500mg	Tablet	
84	D280013	Olanzapine : 5mg (Mouth Dissolving)	Tablet	
85	D010030	Paracetamol Dispersible : 125 mg (Tab)	Tablet	
86	D280042	Paroxetine (Tab) 12.5 mg	Tablet	
87	D04002	Phenobarbitone (Tab) 30 mg	Tablet	
88	D290024	Povidone iodine Gargle 0.5% w/v 50 ml bottle	Oral Solution	
89	D100037	Potassium Chloride oral solution USP 500MG/ 5ML ; 200 ml in amber color bottle	Syrup	
90	D080026	Pregabalin Cap IP 75 mg	Capsule	
91	D360015	Pyrazinamide : 500 mg (Tab)	Tablet	
92	D360016	Pyrazinamide : 750 mg (Tab)	Tablet	
93	D340027	Pyridoxine 100 mg (Tab)	Tablet	
94	D100110	Ramipril 2.5 mg Tablet	Tablet	
95	D040301	Ribaverin 200 mg tab	Tablet	
96	D350050	Silodosin 4mg + Dutasteride 0.5 mg Capsule	Capsule	
97	D060018	Sitagliptin Phosphate : 100 mg (Tab)	Tablet	
98	D14012	Sitagliptin Phosphate : 50 mg (Tab)	Tablet	
99	D250015	Sodium Phosphates Enema BP Each 100ml contains Sodium Dihydrogen phosphate Dihydrate 10% Disodium Hydrogen Phosphate Dodecahydrate 8 %	Enema	
100	D100038	Sodium Valproate Injection 100 mg/ml, 5 ml vial	Injection	
101	D040077	Sofosbuvir : 400mg (Tab)	Tablet	
102	D040088	Spores of poly antibiotic – spores of bacillus clausii 2 billion spores in 5ml Suspension (Strain- O/C, N/R, SIN and T)	Oral Suspension	
103	D020020	Sucralphate Syrup/ Suspension Each 5ml contains Sucralphate 500mg ; 200 ml bottle	Syrup	
104	D160024	Prednisolone 20 mg	Tablet	

105	D040079A	Sofosbuvir 400mg + Velpatasvir 100mg Tablet	Tablet	
106	D250050	Sodium Picosulphate (Tab)	Tablet	
107	D080025	Sodium Valproate 200 mg (Tab)	Tablet	
108	D010035	Tramadol 37.5mg and Paracetamol 325mg (Tab)	Tablet	
109	D260014	Tizanidine 2 mg	Tablet	
110	G-73	Temephos 50% EC	Larvicidal	
111	SACS-17	Tenofovir : 300 mg (Tenofovir Disoproxil Fumarate 300 mg) Tablet	Tablet	
112	D130020	Tiotropium 200 MDI: 9 mcg/ Dose Inhaler(9mcg/ Dose) (Spacer to be provided for each 50)	Inhalational Powder	
113	D280038	Trifluperazine 5mg (Tab)	Tablet	
114	D060084	Vildagliptin : 100 Mg (Tab)	Tablet	
115	D060082	Voglibose 0.2 mg (Tab)	Tablet	
116	D060083	Voglibose 0.3 mg (Tab)	Tablet	

ANNEXURE- XXI

Diagnostic Kits

SN	Item Code	Item Name with Description	Type of Formulation	Quoted/Not Quoted
1	POC12	Dual RDT (HIV and Syphilis) Kit	Diagnostic Kit	
2	Elasa-12	Elisa Kit For hepatitis-C	Diagnostic Kit	
3	Elisa KIT	Elisa Kit for Hepatitis-B	Diagnostic Kit	
4	S-119a	HIV Elisa Test Kit	Diagnostic Kit	
5	RDT(HEP)	Rapid Diagnostic Kit for Hepatitis-B	Diagnostic Kit	
6	RDT(Hepa-c]	Rapid Diagnostic Kit for Hepatitis-C	Diagnostic Kit	
7	RDT-Malaria	Rapid Diagnostic Kit for Malaria	Diagnostic Kit	
8	STK001	Salt testing kit	Diagnostic Kit	
9	S-410	Dengue NS1 Antigen Detection Kit by ELISA	Diagnostic Kit	